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Abstract 
 
Fusion genes occur due to chromosomal instability where two previously separate genes 
rearrange and fuse together, forming a hybrid gene. The first fusions were reported in 
leukemias; however, with the advent of more powerful sequencing technologies, fusions 
have recently been reported in several solid tumors. Using next-generation deep 
sequencing approaches, we discovered a fusion gene connecting the fibroblast growth 
factor receptor 3 (FGFR3) gene to the transforming coiled-coil containing protein 3 (TACC3) 
gene in glioblastoma multiforme. The fusion occurred in 8.3% of patient samples, but not in 
low grade or normal samples.  FGFR3-TACC3 produced an in-frame fusion protein that 
promoted an oncogenic phenotype both in vitro and in vivo. While the fusion was 
overexpressed and contained the majority of the FGFR3 gene, levels of wild-type FGFR3 
were very low. We attributed this effect to the ability of the fusion to bypass miR-99a 
regulation, by losing the 3’ UTR of FGFR3 upon formation of the fusion. The fusion activated 
ERK and STAT3 signaling, and was more sensitive to FGFR, ERK, and STAT3 inhibitors, 
while more resistant to treatment with frontline chemotherapy agent, temozolomide.  
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CHAPTER 1: Introduction 
 
1.1 The Central Nervous System 
The Central Nervous System (CNS) is comprised of the brain and spinal cord. The brain 
serves many important functions, including controlling thought, movement, speech, memory, 
and regulation of internal organs throughout the body. Specialized structures within the brain 
can perform specific tasks. For example, the cerebellum at the back of the brain is 
responsible for fine-tuning motor activity and equilibrium. On the other hand, the cerebrum, 
which forms the majority of the brain, is involved in controlling memory, sensation, vision, 
and hearing, among other important functions.  
The brain is comprised of two major cell types: neurons and glial cells. Neurons are 
responsible for transmitting electrical information from neuron to neuron, across a small 
space called the synapse. This electrical information is transmitted by the release of small 
chemical messengers across the synapse, known as neurotransmitters. The average 
neuron consists of a round cell body that contains the soma where the nucleus is located. 
Projections extend out from the cell body, which make up the dendrites. The cell body is 
then connected to a long structure called an axon, finally terminating at the axon terminal – 
the location where neurotransmitters are released. However, neurons exist in varying 
shapes and sizes depending on their function and location in the brain and peripheral 
nervous system. Neurons can range in size from microscopic dimensions to extending up to 
a meter long and can vary widely in structure.  
Glial cells, from the Greek word meaning “glue”, outnumber neurons by 50 glial cells 
to every one neuron. Glial cells are referred to as “neural helper cells,” and differ from 
neurons in that they can divide, while neurons are post-mitotic cells. Astrocytes are the most 
abundant cell type in the brain and are responsible for clearing excess neurotransmitter from 
the synaptic cleft of firing neurons, in order to prevent neuronal excitotoxicity, or 
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overactivation of a neuron. They are also involved in supplying important nutrients to 
neurons. Oligodendrocytes are responsible for the myelination of the axons of neurons, 
which allows for rapid transmission of information along the axon to the nerve terminal.  
 
1.2 Gliomas  
Gliomas are tumors of the brain and spinal cord, and exhibit poor patient prognosis. Glioma 
accounts for 31% of all primary CNS tumors, and 80% of all malignant primary CNS tumors 
(Central Brain Tumor Registry of the United States http://www.CBTRUS.org). Current 
treatment regimens yield meager benefit, as patients with high grade, invasive glioma, 
known as glioblastoma (GBM), typically do not survive longer than a year following 
diagnosis (Stupp et al, 2009b). Approximately 18,000 new glioma cases will arise every year 
in the US, which will result in 13,000 deaths on average (Central Brain Tumor Registry of the 
United States http://www.CBTRUS.org).  
 Gliomas are named by which cell type they resemble.  For example, ependymoma 
arise from ependymal cells, astrocytomas from astrocytes, oligodendrogliomas from 
oligodendrocytes, etc. Gliomas can also be named by the location in the brain in which they 
occur. For example, optic nerve gliomas occur within the pregeniculate optic pathway, while 
brainstem gliomas occur in the brainstem. Gliomas can further be categorized upon which 
area of the brain they arise from – supratentorial glioma occur in the cerebrum, and 
comprise the majority of adult gliomas while infratentorial gliomas occur in the cerebellum 
and comprise most childhood gliomas.  
The World Health Organization (WHO) grades glioma on a scale from one to four, 
where grade four glioma confer the worst prognosis (Table 1). Grade I gliomas include 
pilocytic astrocytoma and subependymal giant cell astrocytoma, while Grades II-IV include 
diffuse glioma. The mean age of diagnosis varies according to glioma subtype. For example, 
on average pilocytic astrocytoma patients are 17 years old, while GBM, the most deadly 
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form of glioma, confers a median age of diagnosis of 62 years old (Ohgaki, 2005; Ohgaki & 
Kleihues, 2005). The majority of glioma occur in men.   
 
Glioma grade Histology 
I Benign, slow growing, tumor.   
II Relatively slow growing, cells look slightly abnormal, may spread to nearby 
tissues. 
III Malignant, cells look abnormal 
IV Extremely malignant, fast growing, cells recruit abnormal vasculature to 
tumor region, necrotic cells visible. Cells are undifferentiated and 
anaplastic. Grade IV astrocytoma is known as GBM multiforme. 
Table 1. The World Health Organization glioma grading system. 
  
Common molecular alterations in GBM 
Gliomas, like many cancers, typically exhibit more than one genetic mutation, referred to as 
the multi-hit hypothesis (Nordling, 1953). These mutations can involve the deletion of key 
genes, activating mutations, and copy number alterations leading to overexpression of 
oncogenes.  
 The most common genetic alteration in GBM is loss of heterozygosity on 
chromosome arm 10q, which occurs in 60-90% of GBM patients. Tumors can also arise 
when a tumor suppressor gene is lost. Loss of gene expression can occur via deletion, 
methylation, and mutation. One gene in particular that resides on 10q is the phosphatase 
and tensin homolog (PTEN) gene, which is lost in up to 60% of patients with GBM (Wang et 
al, 1997). Upon ligand binding, growth factor receptors recruit PI3 kinase, which 
phosphorylates PIP2 creating PIP3, resulting in activation of Akt, a known oncogene 
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involved in cell proliferation, migration, and angiogenesis. PTEN encodes a tumor 
suppressor protein (Li et al, 1997), which exerts its function by counteracting PI3 Kinase 
activity, secondarily inhibiting the activation of Akt.  
 Three major pathways are mutated in GBM. The first is altered expression, 
activation, or deletion of genes associated with the Tumor Protein 53 (TP53) tumor 
suppressor gene, which occurs in up to 30% of primary GBM (Ohgaki, 2005; Ohgaki & 
Kleihues, 2005). TP53, referred to as the “guardian of the genome”, is located on the short 
arm of chromosome 17. TP53 is responsible for sensing cellular stress and therefore 
facilitating the transcription of target genes involved in cell cycle arrest, DNA repair, or 
cellular metabolism. Examples of cellular stress include oxidative stress, DNA damage, 
osmotic shock, or abnormal oncogene expression. Somatic TP53 mutations are the most 
common genetic alteration in human cancers, occurring in up to 50% of ovarian cancer, 
colorectal cancer, and esophageal cancers (Havrilesky et al, 2003; Hollstein et al, 1990; 
Rodrigues et al, 1990). P53-associated genes are also commonly deregulated in GBM. One 
of these is the murine double minute 2 (MDM2) gene. MDM2, which normally acts as a 
means to negatively regulate TP53, is commonly amplified in GBM and provides a means to 
escape TP53-mediated cell cycle control (Wu et al, 1993). Specifically, MDM2 is involved in 
the ubiquitination and degradation of TP53 protein, and can directly bind to and thereby 
inhibit TP53-mediating transcription (Burton et al, 2002; Thut et al, 1997). Furthermore, the 
CDKN2A locus, which encodes for p14ARF, is frequently inactivated in GBM either by 
deletion or other mechanisms. P14ARF, under normal conditions, inhibits MDM2 thereby 
promoting p53 activity (Moll & Petrenko, 2003; Silva et al, 2003). 
 The retinoblastoma gene (RB) is a tumor suppressor gene involved in cell cycle 
regulation and is dysfunctional in several human cancers (Murphree & Benedict, 1984).  Rb 
protein is expressed from the RB gene located on chromosome 13, and was named 
retinoblastoma as retinoblastoma cancer would develop if both copies of the gene were 
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deleted during development. Like TP53, Rb arrests the cell cycle upon sensing cellular 
stress. An example of cellular stress is when Rb encounters DNA damage. Specifically, Rb 
binds to E2F and DP protein dimers, thereby inhibiting them (Wu et al, 1995), which results 
in G1 arrest (Funk et al, 1997). Other Rb-related genes that are dysregulated in GBM 
include cyclin-dependent kinase (CDK) 4 and CDK6, as well as CDKN2a-P16INK [reviewed 
in (Bralten & French, 2011)].  
Alterations in receptor tyrosine kinase (RTK) pathway signaling constitute another 
major alteration observed in GBM patients. Specifically, the epidermal growth factor receptor 
(EGFR) gene, located on chromosome 7, is aberrantly regulated in up to 50% of GBM cases 
(Cancer Genome Atlas Research, 2008). Activation of EGFR protein leads to activation of 
signaling cascades leading to cell proliferation and migration (Carpenter & Cohen, 1990). 
The EGFR protein is typically membrane bound and becomes activated upon ligand binding, 
resulting in propagation of downstream signaling cascades. EGFR gene deregulation can 
occur via overexpression or by gene mutation. For example, a mutation in the extracellular 
domain of the receptor which occurs by deleting exons 2-7, known as EGFRvIII, results in 
translation of a protein that does not contain the canonical ligand binding domain and is 
constitutively activated. Interestingly, overexpression of WT receptor usually co-occurs with 
expression of EGFRvIII (Ekstrand et al, 1991).  Overexpression of other RTKs, including the 
platelet-derived growth factor (PDGF) family are also common in GBM (Hermanson et al, 
1992).  PDGFs are growth factors that regulate cell proliferation and vascular proliferation. 
There are four isoforms of PDGF, PDGFA-PDGFD, and two different types of receptors, 
PDGFRA and B. PDGF ligands are also overexpressed in GBM [reviewed in (Nazarenko et 
al, 2012)].  
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Current standard of care 
Currently, there is no known cure for GBM. Patients diagnosed with GBM exhibit a median 
survival of 14 months following diagnosis (Stupp et al, 2009b). Several factors contribute to 
the deadliness of these tumors. First, GBM are highly heterogeneous tumors, containing 
several different cell clones and molecular signatures. Secondly, GBM cells are often 
resistant to most chemotherapy, including TMZ, and as a result typically recur. Finally, due 
to the location of these tumors, they may invade areas of the brain that are vital to bodily 
function, making tumor resection exceedingly difficult and compromise neurological 
morbidity that compromise function. 
 Upon initial diagnosis of a patient with GBM, a surgeon will attempt to surgically 
remove as much of the tumor as possible without hurting normal, healthy tissue surrounding 
the tumor. Sometimes the tumor exists in areas of the brain that make complete resection 
unlikely. However, partial resection alone provides immense benefit for the patient to 
alleviate symptoms associated with the tumor, such as relieving pressure created by the 
tumor. Further, removing a portion or completely removing the tumor allows physicians to 
properly diagnose the patient, in order to recommend the most suitable next course of action 
for the patient. During surgery, the brain of the patient is visualized using imaging and 
monitoring techniques. Some of these imaging techniques include computerized 
tomography, magnetic resonance imaging, positron emission tomography, and angiography 
(to map blood vessels). All of these techniques are available to help the surgeon determine 
the tumor boundaries in order to distinguish the tumor from normal tissue. Following surgical 
removal, the patient is typically treated with radiotherapy and adjuvant chemotherapy with 
TMZ (Stupp et al, 2009a).  
Radiation is typically administered two to four weeks following surgery. There are 
three main types of radiotherapy. The most conventional type, called External Beam 
Radiation Therapy (EBRT), uses a machine that guides radiation from outside of the body. 
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Brachytherapy involves implanting a radioactive device in or near the tumor. This type of 
treatment is the most recent advance in radiotherapy. In some instances, patients are 
offered the opportunity to join clinical trials testing new radiotherapy techniques. Because 
radiation kills normal, healthy cells in addition to tumor cells, radiation is typically not given 
repeatedly if the tumor recurs. Radiotherapy combined with surgery has been shown to 
prolong survival compared to performing surgery alone, however the efficacy of radiotherapy 
varies between patients (Stupp et al, 2009b). 
Chemotherapy treatment has been found to prolong survival in 25% of patients with 
GBM (Fine et al, 1993). The frontline chemotherapy agent for GBM is called temozolomide 
(TMZ). The United States Food and Drug Administration approved TMZ in 2005, as it was 
found to provide a survival benefit while being well tolerated by the patient. TMZ is prodrug 
that is metabolized by the body to produce the active compound (Figure 1). TMZ exerts its 
DNA damaging effects by alkylating and methylating DNA at either N-7 or O-6 positions on 
guanine residues. This resulting methylation triggers the DNA damage response, leading to 
death of these cells. The ability of cancer cells to bypass TMZ-induced cell death can be 
partly due to the activity of the O-6-methylguanine-DNA-methyltransferase (MGMT) protein. 
Specifically, MGMT is able to remove methyl groups added on my TMZ, thus it reverses 
DNA damage and promotes cell survival (Jacinto & Esteller, 2007). Tumors that lack MGMT 
expression by either epigenetic modification or gene deletion may respond better from 
treatment with TMZ (Stupp et al, 2009b).  
With the advent of sophisticated molecular profiling techniques came the push to 
provide personalized medicine. A major phenotype observed with GBM is profound vascular 
proliferation around the tumor site, which provides vital nutrients allowing the tumor to grow 
and invade nearby tissues. Therefore, the FDA approved the anti-angiogenic drug 
bevacizumab (Avastin) in 2009 [Avastin Approval History. U.S. Food and Drug 
Administration]. Furthermore, patients harboring RTK mutations such as the EGFRvIII 
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mutation showed modest improvements with RTK inhibitors gefitinib or erolotinib (Rich et al, 
2004). Current research is focusing on the use of immunotherapy, gene therapy, and more 
sophisticated targeted therapies for the treatment of GBM. Furthermore, the blood brain 
barrier (BBB) prevents many agents from reaching the brain, and therefore from providing 
full therapeutic potential. Therefore, current research is focusing on more effective drug 
delivery mechanisms to deliver these potent compounds to diseased tissue within the brain. 
Furthermore, major hurdles involved in treating GBM patients involve overcoming the BBB. 
 
Figure 1. Molecular structure of TMZ. 
 
1.3 Fusion genes 
The rearrangement of genetic material inside of a cell, known as genomic instability, can 
lead to the formation of cancer and other various maladies. Genomic instability is a cellular 
state that allows the existence genomic alterations such as single nucleotide 
polymorphisms, gene deletions and amplifications, gene translocations, among other 
events.  
Several factors can lead to genomic instability by damaging DNA, such as radiation, 
tobacco, or ultraviolet light. Genetic instability can also result from mutating the DNA repair 
process leading to faulty DNA repair. A consequence of genome instability is the formation, 
mutation, or overexpression of proto-oncogenes, as well as activating mutations in these 
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genes. On the other hand, genome instability can lead to the deletion or decrease in 
expression of tumor suppressor genes.  
Another type of genetic event occurs when a particular gene moves to another 
location on a chromosome, “linking” itself to another gene, forming a hybrid gene. This can 
also happen when a segment of DNA in between two consecutive genes on a chromosome 
is deleted. The result of these genetic changes produces a fusion gene. Fusion genes can 
also contain more than two genes. Fusion genes have been discovered and characterized in 
a variety of different cancers, ranging from blood leukemias to solid tumors.  
In 1973 the first fusion gene was discovered in chronic myeloid leukemia (CML). This 
fusion contained the central portion of the breakpoint cluster region (BCR) gene fused to the 
second exon of the abelson murine leukemia viral oncogene homolog 1 (ABL1) gene 
(Lifshitz et al, 1988; Nowell & Hungerford, 1960; Rowley, 1973a). Since the initial discovery 
of this fusion, BCR-ABL1 has been found to occur in more than 95% of CML patients 
(Dreazen et al, 1987). This fusion is oncogenic as it encodes a constitutively active ABL1 
kinase (Shtivelman et al, 1985b). Since the discovery of BCR-ABL1, dozens of fusions have 
been identified in both hematological and solid cancers, several of which exhibit vast 
therapeutic benefit when targeted.  
 
Fusion discovery mechanisms 
The detection and discovery of fusion genes correlated with the development of more 
powerful experimental methodologies. Previous use of cytogenetic analysis, such as 
fluorescent in situ hybridization (FISH) would only detect fusions that contained a significant 
translocation. Examples of fusions produced by translocations that can be detected by this 
method are the EML4-ALK fusions in lung cancer (Martelli et al, 2009), and BCR-ABL1 
fusions in CML (Shtivelman et al, 1985a). Fusions that cause a particular fusion partner to 
be overexpressed can be diagnosed via microarray, such as the TMPRSS2-ERG fusions in 
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prostate cancer (Tomlins et al, 2007; Tomlins et al, 2005a). Another example of this is the 
MYB-NFIB fusion in adenoid cystic carcinoma.  This fusion contains the majority of the MYB 
gene, and only lacking the 3’ untranslated region (UTR) of this gene, connected to the last 
coding exon of NFIB. The MYB gene is normally under tight regulation by miR-15a/16 and 
miR-150, negatively regulating gene expression. However, because this fusion lacks the 3’ 
UTR of MYB, this leads to overexpression of the MYB protein (Persson et al, 2009). 
Therefore, this is another case where microarray could be used to identify a MYB-NFIB 
positive patient sample. With the advent of more powerful and sophisticated sequencing 
technologies came the discovery of fusion genes in a diverse array of cancers (Figure 2; 
Table 2). The first available sequencing technique lead to the published sequence of the lac 
operon, in 1972 (Gilbert & Maxam, 1973). Soon thereafter, a more powerful technology was 
developed, termed Sanger sequencing (Sanger et al, 1977). Although this technology is 
nearly 40 years old to date, it is still widely used in research laboratories today. In 1983, the 
polymerase chain reaction (PCR) was developed by the American biochemist Kary Mullis, 
which revolutionized biochemistry and molecular biology (Saiki et al, 1985). Applied 
Biosystems developed the first automated DNA sequencer in 1987, which profoundly 
decreased experiment effort and overall duration (Wade, Nicholas. 2000). 
 
Fusion name Discovery year Discovery method Reference 
BCR-ABL1 (CML) 1960 Cytogenetic 
analysis 
(Rowley, 1973a) 
IGH-MYC 1972 Cytogenetic 
analysis 
(Manolov & 
Manolova, 1972) 
ESWR1-FLI1 1983 Cytogenetic 
analysis 
(Aurias et al, 
1983) 
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SS18-SSX1 1987 Cytogenetic 
analysis 
(Turc-Carel et al, 
1987) 
PML-RARA 1990 Cytogenetic 
analysis 
(Larson et al, 
1984) 
EWSR1-ATF1 1990 Cytogenetic 
analysis 
(Bridge et al, 
1990) 
ETV6-NTRK3 1998 Cytogenetic 
analysis 
(Knezevich et al, 
1998) 
PAX8-PPARG 1999 Cytogenetic 
analysis 
(Kroll et al, 
2000) 
MECT1-MAML2 2003 Cytogenetic 
analysis 
(Tonon et al, 
2003) 
TMPRSS2-ERG 2005 Microarray 
technology 
(Tomlins et al, 
2005b) 
TMPRSS2-ETV1 2005 Microarray 
technology 
(Tomlins et al, 
2005b) 
EML4-ALK 2007 PCR technology 
followed by Sanger 
sequencing 
(Soda et al, 
2007) 
KIAA1549-BRAF 2008 PCR technology 
followed by Sanger 
sequencing 
(Jones et al, 
2008) 
MYB-NFIB 2009 Cytogenetic 
analysis 
(Persson et al, 
2009) 
ESRRA-C11orf20 2011 Next-generation (Salzman et al, 
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sequencing  2011) 
FGFR3-TACC3 
(GBM) 
2012 Next-generation 
sequencing 
(Singh et al, 
2012) 
FGFR3-TACC3 
(BC) 
2012 RT-PCR following 
by Sanger 
sequencing 
(Williams et al, 
2013b) 
PTPRK-RSPO3 2012 Next-generation 
sequencing 
(Seshagiri et al, 
2012) 
EIF3E3-RSPO2 2012 Next-generation 
sequencing 
(Seshagiri et al, 
2012) 
SFPQ-TFE3 2013 Next-generation 
sequencing 
(2013) 
 
Table 2. Fusion genes and their methods of discovery. Taken with permission from Parker, 
B.C., and Zhang, W. (2013). Fusion genes in solid tumors: an emerging target for cancer 
diagnosis and treatment. Chinese journal of cancer 32, 594-603. 
 
Several factors hindered DNA sequencing at this time, including the cost, time, and 
manpower it took to sequence a sample. In 2005 came the development of a high-
throughput, low cost sequencing platform, known as next-generation sequencing. This 
highly sophisticated platform revolutionized genetic sequencing and allowed the production 
of millions of read sequences concurrently, allowing quicker and easier detection of 
chromosomal abnormalities across disease samples (Schuster, 2008). Specifically, the 
detection of fusion genes was completely transformed and was light years easier compared 
to conventional detection methods.  
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Figure 2. Fusion discovery coincides with sequencing technology. Taken with 
permission from Parker, B.C., and Zhang, W. (2013). Fusion genes in solid tumors: an 
emerging target for cancer diagnosis and treatment. Chinese journal of cancer 32, 594-603. 
 
Fusions that do not produce a highly overexpressed protein, or that arise via focal 
chromosomal rearrangements would go undetected in conventional methodologies. 
Therefore, the advent of next-generation sequencing allowed researchers to find these hard 
to find fusions, which helped shed light on the importance of these particular chromosomal 
aberrations, and how we can utilize them as therapeutic targets in many cancers. Although 
fusion events were originally associated with hematological malignancies, increasing 
numbers of fusions have been discovered in solid tumors(Figure 3).  
 27 
 
Figure 3. Locations of fusion genes that occur in solid tumors. Used with permission from 
Parker, B.C., and Zhang, W. (2013). Fusion genes in solid tumors: an emerging target for 
cancer diagnosis and treatment. Chinese journal of cancer 32, 594-603. 
 
Types of fusion genes 
 Fusion genes can arise via a variety of mechanisms resulting from chromosomal 
instability (Figure 4). A fusion forms by deletion when a segment of DNA between two 
consecutive genes on the same chromosome is deleted, resulting in the union of upstream 
and downstream genes. An example of a fusion that forms via deletion is the TMPRSS2-
ETS transcription family (ERG, ETV1, and ETV4) fusion in prostate cancer, which fuses the 
promoter region of TMPRSS2 to members of the ETS family transcription family. Expression 
of the TMPRSS2 gene is androgen driven. Therefore, formation of this fusion causes the 
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expression of the ERG, ETV1, or ETV4 genes to be regulated in an androgen-dependent 
manner, leading to their overexpression of these oncogenic signaling proteins (Tomlins et al, 
2005a).  
 Fusion genes can also arise via translocation. Translocation occurs when a segment 
of DNA moves to another location, or when two chromosome arms switch. An example of a 
fusion gene that results via translocation is the BCR-ABL1 fusion. This fusion forms when 
chromosomes 9 and 22 switch, forming what is called the Philadelphia chromosome 
(Biesecker et al, 1973). This fusion is oncogenic as it encodes a constitutively active form of 
the oncogenic ABL kinase (Shtivelman et al, 1985a). And finally, fusion genes can form via 
inversion, where a segment of DNA is inverted, creating a fusion. An example of a fusion 
forming via inversion is the EML4-ALK fusion in lung cancer, which forms via a small 
inversion on chromosome arm 2p (Soda et al, 2007).  
 
Figure 4. Mechanisms of fusion gene formation. Used with permission from Annala, M.J., 
Parker, B.C., Zhang, W., and Nykter, M. (2013). Fusion genes and their discovery using high 
throughput sequencing. Cancer letters 340, 192-200. 
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Therapeutic targeting of fusion genes 
Fusion genes are attractive in cancer research because they can serve as prognostic 
markers, diagnostic tools, and can be used as therapeutic targets. The ability to exploit 
fusion genes as therapeutic targets was first realized with the BCR-ABL1 fusion in CML. As 
mentioned previously, the fusion encodes a constitutively activated ABL1 RTK. Targeting 
the fusion by using the ABL1 inhibitor imatinib substantially prolonged patient survival with 
patients harboring the BCR-ABL1 fusion. Similarly, the PML-RARA fusion, found in up to 
95% of acute promyelocytic leukemia patients, can be targeted by using tretinoin (all-trans 
retinoic acid). Clinical trials using tretinoin on PML-RARA positive patients have revealed 
impressive therapeutic benefits for these patients (Castaigne et al, 1990; Huang et al, 1988; 
Larson et al, 1984). The first fusion to be targeted in solid tumors was the EML4-ALK fusion, 
found in 5% of lung cancer patients (Soda et al, 2007). Fusion positive patients were treated 
with the ALK inhibitor critzotinib, which benefited patient survival (Camidge & Doebele, 
2012).  
Ewing sarcoma is a highly metastatic class of sarcoma and is the second most 
frequent bone tumor subtype in children. Fusions between the EWSR1 gene and ETS family 
of transcription factors occur in approximately 90% of these patients, and are produced via 
translocation between chromosomes 11 and 22. The first detected fusion genes in sarcoma 
were found in a patient with Ewing sarcoma in 1983 (Aurias et al, 1983; Delattre et al, 1993; 
Turc-Carel et al, 1983). Evidence suggests that this fusion is correlated with high expression 
levels of the insulin-like growth factor 1 receptor (IGF-1R) (Scotlandi et al, 1996), a 
transmembrane receptor that promotes cellular transformation and survival (Shelton et al, 
2004), and that is upregulated in malignant tissues (LeRoith & Roberts, 2003). Efforts to 
generate a targeted therapy for EWSR1-FLI1 positive patients led to the development of 
molecules that inhibit IGF-1R. Although preclinical studies in the laboratory showed 
potential, when brought to the clinic only a subset of patients with this fusion benefitted from 
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IGF-1R inhibition (Olmos et al, 2011). Therefore, current efforts are dedicated to the 
identification of a predictive measure to identify patients who are positive for the ESWR1-
FLI1 fusion who would benefit from IGF-1R targeted therapy.  
 
1.4 Fibroblast Growth Factor Receptor family 
The fibroblast growth factor receptor (FGFR) family contains membrane bound receptors 
that bind to members of the fibroblast growth factor ligand family (over 22 known ligands) 
(Ornitz & Itoh, 2001). These receptors contain an extracellular ligand-binding domain, which 
consists of three immunoglobulin-like (IgI-III) domains, a transmembrane domain, and an 
intracellular domain that possesses tyrosine kinase activity. Upon ligand binding to the 
extracellular domain, receptors dimerize and the C-terminal domain is then 
autophosphorylated. This leads to recruitment of adaptor proteins such as grb2, which links 
active receptors to JAK/STAT3, ERK, and Akt signaling pathways (Dailey et al, 2005). 
Activation of FGFRs leads to a plethora of functional consequences, including cellular 
differentiation, proliferation, survival, and migration. There are five members of the FGFR 
family. FGFRs 1-4 contain the canonical structure as described above. However, FGFR5 
lacks a cytoplasmic tyrosine kinase domain (Sleeman et al, 2001).  
 
FGFR expression 
FGFR family members are differentially expressed both spatially and temporally, and exhibit 
preferential ligand binding specificity. Furthermore, each family member can undergo 
alternative splicing, yielding isoforms that are expressed in specific tissues. For example, the 
extracellular Ig-III domain of FGFR3 can be alternatively spliced yielding IIIb and IIIc 
isoforms, which are expressed in epithelium and mesenchyme, respectively (reviewed in 
(Holzmann et al, 2012)).  In adult tissues, FGFR1 is highly expressed in cardiac myocytes, 
epithelial cells of the heart, pituitary gland, thymus, and cornea, while absent from the 
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epithelial lining of the stomach. FGFR2 is widely expressed in the brain, ovary, and gastric 
epithelium. FGFR3 is highly expressed in bone and cartilage, as well as the pancreas. 
FGFR4 has a more limited distribution, and is observed in the gastrointestinal system 
(Hughes, 1997). 
 FGF ligands are also expressed differentially. FGF-1 and FGF-2 are diffusely 
expressed across adult tissues (Hughes et al, 1993), while other ligands are expressed at 
different times during development, and vary among tissue types. For example, FGF3, -5, 
and -4 are mainly expressed during development, but not in adult tissues (Jakobovits et al, 
1986; Yoshida et al, 1988).   
 
FGFR and cancer 
Several cancers exhibit abnormal FGFR signaling [reviewed in (Dieci et al, 2013)]. For 
example, FGFR1 mutations have been observed in prostate cancer (Giri et al, 1999) and in 
GBM (Rand et al, 2005), while FGFR1 amplifications are found in lung and breast cancers 
(Theillet et al, 1993; Weiss et al, 2010). Moreover, aberrant FGFR2 signaling occurs in 
breast, gastric, and endometrial cancers (Antoniou et al, 2008; Byron et al, 2012; Jang et al, 
2001). FGFR3 is also implicated in cancer. For example, nearly 50% of bladder cancer 
cases exhibit an activating mutation in the extracellular portion of the FGFR3 (van Rhijn et 
al, 2002), and the receptor is overexpressed in up to 20% of multiple myeloma patients 
(Chesi et al, 1997). Furthermore, about 7%-8% of rhabdomyosarcoma patients harbor 
FGFR4-activating mutations and receptor overexpression (Taylor et al, 2009). 
 
1.5 Transforming Acidic Coiled-Coil Containing Protein 3  
The transforming acidic coiled-coil containing protein 3 (TACC3) gene is located on 
chromosome location 4p16.3 and encodes a protein that plays a role in mitotic spindle 
stabilization during mitosis (Gergely et al, 2000). TACC3 is a member of the TACC family of 
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proteins, which consists of three proteins that are conserved throughout metazoans. The N-
terminal domain of TACC3 contains several phosphorylation sites, while the C-terminal 
contains a coiled-coil domain. TACC3 is highly expressed in proliferative cell types and 
regenerative tissues (Hao et al, 2002), and TACC3 knockout mice confer embryonic lethality 
(Piekorz et al, 2002). TACC3 activity is tightly regulated by Aurora Kinase A 
phosphorylation, which causes TACC3 to localize to the centrosomal proximal spindle 
during pro-metaphase (Barros et al, 2005). Other TACC3-interacting molecules include the 
MT polymerase family XMAP215, which is critical for the growth of centrosomal 
microtubules (Barros et al, 2005).  
 
TACC3 and cancer 
The human TACC1-3 genes are located on chromosomes whose regions show genetic 
aberrations in many cancers and neurological diseases [reviewed in (Ha et al, 2013a)]. For 
example, the TACC1 and TACC2 genes are commonly amplified in breast cancer, and are 
associated with worse patient prognosis as well as cancer recurrence (Cheng et al, 2010; 
Chin et al, 2006). The TACC3 gene was found to be overexpressed in GBM, and correlated 
with expression of Aurora Kinase A (Duncan et al, 2010). TACC3 was also found to be 
upregulated in lymphoma cases, as well as multiple myeloma (Chakraborty et al, 2008; 
Keats et al, 2003).  
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CHAPTER 2: Materials and methods 
Tumor samples. 40 human glioma samples (20 GBM; 5 anaplastic astrocytoma; 6 anaplastic 
oligodendroglioma; 9 oligodendroglioma) were acquired from University of Texas MD 
Anderson Cancer Center’s Brain Tumor Center tissue bank. 51 human glioma samples (28 
GBM; 23 low-grade glioma) were acquired from the Tumor Tissue Bank of the Tianjin 
Medical University Cancer Institute and Hospital. Tissues were obtained from surgery and 
snap frozen. Dr. Kexin Chen’s group performed the RT-PCR validation experiments on 
Tianjin samples.  
RNA extraction for transcriptome sequencing. While frozen, each tissue (weighing up to 50 
mg) was transferred to a liquid nitrogen–cooled mortar and pestle, crushed into powder, and 
dissolved in 1 ml TRIZOL reagent (Invitrogen). Chloroform (200 μl) was added to the sample, 
which was then vortexed at high speed for 15 seconds and centrifuged at 12,000 g for 15 
minutes at 4°C. The aqueous phase was transferred to a fresh 1.5-ml Eppendorf tube, and 
an equal volume of 70% ethanol was added and the contents mixed by tube inversion. A 
Qiagen RNeasy mini column (Qiagen) was used to further purify the sample. The column 
was washed twice with 500 μl RPE buffer (Qiagen), and RNA was eluted with 50 μl 
nuclease-free water. The RNA was quantified using a spectrophotometer. RNA integrity was 
verified using an Agilent 2100 BioAnalyzer. Poly-A selection was not performed on any of 
the sample pools. 
Sample pooling. Samples were pooled for SOLiD sequencing according to tumor type. GBM 
samples were divided into four pools of five tumor samples. Anaplastic astrocytoma and 
anaplastic oligodendroglioma samples were pooled into two separate pools, and the 
oligodendroglioma samples were further split into two pools. Two pools of commercial 
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normal brain RNA (Ambion) were also acquired: one pool contained RNA from adult brain, 
the other from fetal brain. 
Library preparation for whole transcriptome sequencing. Libraries for both whole 
transcriptome and small RNA sequencing were prepared using the small RNA expression kit 
from Applied Biosystems Inc. (PN 4397682; Life Technologies Corp.), based on the SOLiD 
System whole transcriptome and small RNA sequencing protocols provided by Applied 
Biosystems. This was performed by the MDACC sequencing core headed by Dr. 
Changgong Liu.  rRNA was depleted from total RNA using the Invitrogen Ribominus 
Eukaryotic Kit (PN A1083708; Life Technologies Corp.), and 0.5–1.0 μg rRNA-depleted total 
RNA was fragmented using RNase III. The fragmented rRNA-depleted total RNA was 
hybridized and ligated with truncated adaptor mix A from the SOLiD small RNA expression 
kit. Next, reverse transcription was performed to generate cDNA templates. cDNA was size 
selected from Novex 6% TBE-urea gel (Invitrogen). The excised gel piece containing DNA 
100–200 bp in length was split vertically into four pieces using a razor blade. The size-
selected cDNA was further amplified using the supplied primer set containing a six-base-
long sequence-specific barcode in approximately 12–15 cycles of PCR. The purified PCR 
products with barcodes served as a library. Libraries ranged in size from 150 to 
approximately 250 bp and contained 50- to 150-bp cDNA inserts, quantitated and qualitated 
by Agilent Bioanalyzer 2100. 
Library preparation for small RNA sequencing. The sample containing small RNA was 
hybridized with truncated adaptor mix A provided in the small RNA expression kit. The 
adaptor mixes were sets of RNA/DNA oligonucleotides with a single-stranded degenerate 
sequence at one end and a defined sequence required for SOLiD sequencing at the other. 
Hybridizing and ligating the sample with adaptor mix A sequentially yielded the template for 
SOLiD sequencing from the 5′ end of the small RNA. The small RNA population of 18–40 nt 
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ligated with adaptor mix A was reverse transcribed to generate cDNAs. To meet the sample 
quantity requirement for SOLiD sequencing and to append the required terminal sequences 
to each molecule, the cDNA libraries were amplified using one of the supplied primer sets 
containing a six-base-long sequence-specific barcode in approximately 12–15 cycles of 
PCR. The individual library PCR products, containing small RNA of 18–40 nt with 
barcode(s), were purified and size-selected for 108–130 bp by electrophoresis on 6% 
polyacrylamide gel. 
Template bead preparation. The individual prepared library was quantitated and titrated, 
before multiplexing, as pooled templates for emulsion PCR; the template molecules were 
attached to 1 μm beads as described in the Applied Biosystems SOLiD emulsion PCR 
protocol. After emulsion PCR, the template beads with amplified monoclonal templates were 
enriched by adaptor P2-affinity binding of polystyrene beads in 60% glycerol gradient by 
centrifugation. The P2-enriched template beads were further modified by terminal 
transferase with oligo linker for immobilization to the slide and prepared for deposit on 
substrate-coated glass slides, as described in the Applied Biosystems protocol. 
Sequencing. Sequencing runs were performed on SOLiD version 3.5 for both whole 
transcriptome RNA sequencing and small RNA sequencing. The library template beads 
were titrated by workflow analysis to determine the percentage of P2-positive beads in the 
total template before they were deposited onto slides for sequencing. The number of P2-
positive template beads deposited in full chambers of slides with multiplexed five barcoded 
whole transcriptome libraries and performed in 50 nt of whole transcriptome sequencing, 
and of P2-positive beads of 10 pooled barcoded libraries on full slide for small RNA 
sequencing in 35 nt small RNA sequencing, was determined. The average depth of 
colorspace reads per sample pool was 6.7 × 107. 
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Fusion gene discovery. To identify fusion gene candidates, RNA-seq reads from each 
sample pool were aligned against transcripts from NCBI RefSeq 38. Reads that aligned to 
known transcripts were assumed to result from normal transcription and were discarded 
from further analysis. The 5′ and 3′ ends of unaligned reads were split into two anchors, 
each 18 colors in length. The paired anchors were aligned against human exon sequences 
from NCBI RefSeq 38. Anchors with more than three alignments against the exome were 
discarded as noninformative. Since anchors were short, no mismatches against the 
reference exon sequences were allowed in anchor alignments. For each read with 
alignments for both anchors, a list of anchor-based exon-exon junctions was generated by 
taking a Cartesian product of the two sets of exons to which the anchors aligned. If an 
anchor pair aligned to an exon-exon junction between two exons from the same gene, all 
junctions for that anchor pair were discarded, because the read was assumed to originate 
from some form of unannotated transcription or splicing. We were then left with fusion 
candidates represented by exon-exon junctions between distinct genes. Once we had the 
lists of anchor-based junctions for every sample, we combined them and verified the 
junctions by aligning the full transcriptome-unaligned reads against them. 
To reduce the number of false positives, each fusion candidate was required to fulfill the 
following requirements (Supplemental Figure 1). (a) The fusion candidate must not involve 
rRNA genes or other highly abundant genes, and must not involve genes located at 
hypervariable genomic sites. The list of blacklisted gene name patterns included RN18S1, 
RN28S1, RPPH1, SNORD*, SNORA*, RNY*, RN7SL, RN7SK, RNU*, and HLA-*. (b) Full 
50-base reads aligning to the fusion candidate must together cover at least 15 bases on 
both sides of the fusion junction. (c) The fusion candidate must not be found in Ambion 
commercial normal brain samples. (d) The fusion candidate’s supporting reads must not 
contain more than an average of 0.7 nt mismatches per read against the reference 
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transcriptome. (e) The 3′ side of the fusion junction must have no perfect alignments against 
any sequence within 50 kb of the genomic alignment for the 5′ side of the fusion junction. 
The 5′ side of the fusion junction must have no perfect alignments against any sequence 
within 50 kb of the genomic alignment for the 3′ side of the fusion junction. 
For each fusion fulfilling these requirements, we counted the number of reads in each of the 
8 tumor sample pools and calculated a P value using the Pearson χ2 test to compare 
goodness-of-fit against a uniform reference distribution. Fusions were then ranked in 
ascending order by P value, so that fusions whose read distributions deviated most 
significantly from a uniform distribution were ranked at the top. In total, we identified 17,564 
putative fusion junctions supported by one or more RNA-seq reads; filtering yielded a 
ranked list of 52 fusion candidates. 
Small RNA expression analysis based on sRNA-seq. Small RNA sequencing reads were 
trimmed to a length of 18 colors and aligned against mature microRNA sequences from 
miRBase version 14 using Bowtie (Langmead et al, 2009). Mature microRNA expression 
levels were calculated by counting reads that aligned completely within an annotated mature 
microRNA site in the pre-microRNA sequence. Trimming of reads to 18 colors prior to 
alignment was necessary because the sRNA-sequence protocol resulted in reads that 
included a 3′ adapter sequence. The trimming step also allowed us to effectively calculate 
the expression level of each microRNA as the sum of its iso-miR expressions. MicroRNA 
expression levels were normalized by the total number of mappable reads per sequencing 
experiment (Moore et al, 2013). 
RT-PCR validation of fusion transcripts. To create a mammalian expression vector, cDNA 
was synthesized using SuperScript III (catalog no. 18080-051; Invitrogen) and random 
hexamers followed by PCR amplification using Advantage HD polymerase mix (639241; 
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Clontech) withFGFR3 primer TCGCCAGTCTCCCGAGC and TACC3 primer 
GACAGCGGCTCCGTGGAGG. The fusion PCR products were TOPO cloned (45-0640; 
Invitrogen). Finally, the MSC enzymes BamHI and XbaI were used to move the fusion genes 
into pcDNA3.1+. All final constructs were sequence verified. 
Immunoblot validation of fusion proteins. Total protein was isolated from tumor tissue by 
subjecting it to lysis buffer (1× RIPA containing 0.1% Halt protease) and phosphatase 
inhibitor cocktail (Fisher Scientific) and brief sonication (Branson Digital Sonifer Model 450) 
at 10% amplitude, followed by rotation at 40°C for 30 minutes. Total protein was isolated by 
centrifugation at 1,214 g for 15 minutes, and lysates were stored at –80°C. 
Cloning. cDNA (random primed, superscript III) was made from GBM-13, the patient sample 
with the highest detected fusion level. The complete 3.0-kb fusion transcript was amplified 
using the forward primer 5′-TCGCCAGTCTCCCGAGC-3′ (upstream of the FGFR3 start 
codon) and the reverse primer 5′-GACAGCGGCTCCGTGGAGG-3′ (downstream of 
the TACC3 stop codon) with the Clontech Advantage — LA polymerase kit (catalog no. 
639152). The PCR product was cloned into pCR2.1 (catalog no. K4500; Invitrogen). An 
error-free subclone was created in pcDNA3.1 (by way of a pBluescript II intermediate to pick 
up required HindIII-Xba cloning sites). WT FGFR3 andTACC3 constructs were purchased 
(Origene) and subcloned into the pcDNA3.1 expression vector. 
Cell line generation and immunoblotting. All tissue cultures were maintained in DMEM/F12 
medium supplemented with 10% FBS in a 37°C humidified incubator containing 5% CO2. 
Control cell lines containing pcDNA3.1 expression vector only were obtained as previously 
described (Wang et al, 2003). The FGFR3-TACC3 construct sequenced from GBM-13 was 
inserted into the pcDNA3.1 expression plasmid (Invitrogen) under control of the 
cytomegalovirus promoter. 6 × 105 SNB19 and U251 cells were transfected with 10 
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mg FGFR3-TACC3, WT FGFR3, or WT TACC3 cDNA with Lipofectamine (Invitrogen) per 
the manufacturer’s instructions. Stably transfected cells were selected for with 0.4 mg/ml 
G418 (Invitrogen) for two weeks, after which SNB19 clones were selected and amplified. 
Relative expression of either WT FGFR3 or the FGFR3-TACC3 fusion between SNB19 cell 
clones and the mixed population was measured by immunoblot analysis using a mouse 
monoclonal antibody probing for FGFR3 amino acids 25–124 (sc-13121; Santa Cruz 
Biotechnology Inc.). Downstream analysis after FGFR3-TACC3 fusion overexpression was 
performed, probing for β-tubulin (9F3), phosphorylated STAT3 (Tyr705; 3E2), total STAT3 
(79D7), phosphorylated p44/42 MAPK (ERK1/2; Thr202/Tyr204), total p44/42 MAPK 
(ERK1/2), vimentin, lamin B, GAPDH, and totalTACC3 (Santa Cruz Biotechnology Inc.) 
miR-99a reporter gene assay. The 3′-UTR of FGFR3 in the pMirTarget reporter vector was 
purchased from Origene Technologies Inc. The miR-99a binding site was mutated using 
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies), creating a 
deleted mutant from 5′-AAUACGGGUA-3′ to 5′-AA––––––UA-3′. To test the ability of miR-
99a to target the 3′-UTR of FGFR3, WT and mutant constructs were transfected into SNB19 
cells concurrently with TK Renilla luciferase reporter vector (Promega) and either control 
(scrambled) microRNA or miR-99a mimic (Thermo Fisher Scientific). At 48 hours after 
transfection, cells were assayed for relative luciferase activity using the Dual-Luciferase 
Reporter Assay System (Promega). Transfections were replicated in 9 independent 
experiments. In each experiment, relative luciferase activity following miR-99a 
overexpression was normalized to scrambled controls and converted to a log ratio. An 
unpaired 1-tailed t test was used to determine whether the log ratios were different between 
WT FGFR3 UTR and deletion mutant cells. 
qRT-PCR validation of successful miR-99a transfection in SNB19 cells. To confirm 
successful transfection, miR-99a mimic (300516-03), anti–miR-99a (IH-300516-05), and 
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scrambled (control) microRNA (Thermo Fisher Scientific) were transfected into SNB19 
parental cells with 9 biological replicates (transfections) per group. For each of the biological 
replicates, miR-99a (assay ID 000435; Applied Biosystems) levels were quantified using 
TaqMan qRT-PCR (microRNA protocol 4364031 revision B; Applied Biosystems) with 3 
technical replicates that were averaged and normalized to endogenous U6 (assay ID 
001093; Applied Biosystems). A 2-tailed Mann-Whitney Utest was used to assess whether 
miR-99a/U6 log ratios differed between groups. 
qRT-PCR validation of FGFR3 mRNA level regulation by miR-99a, miR-21, and miR-
125b.miR-99a mimic (300516-03), anti–miR-99a (IH-300516-05), miR-21 mimic (C-301023-
01), miR-125b mimic (C-300595-03), or scrambled (control) microRNA (Thermo Fisher 
Scientific) were transfected into SNB19 parental cells with nine biological replicates 
(transfections) per group. 0.5 μg total RNA from each transfection was reverse transcribed 
in 20-μl reactions. A ratio of 1 μg total RNA to 0.4 μg random hexamers was maintained, 
and the mixtures were heated at 70°C for 10 minutes. The tubes were then incubated at 
room temperature for 10 minutes, and the following components were added: 1× Superscript 
II RT Buffer (Invitrogen), 10 mM dithiothreitol (Invitrogen), 0.5 mM dNTPs (ISC Bioexpress), 
20 U RNase Inhibitor (Ambion), and 200 U Superscript II Reverse Transcriptase (Invitrogen). 
The reaction was again incubated for 10 minutes at room temperature and then held at 37°C 
for one hour. The reaction was incubated at 42°C for 1.5 hours and then at 50°C for 30 
minutes. Real-time PCR was performed on the Applied Biosystems Prism 7900 using 
an FGFR3 assay (Hs00179829_m1; Applied Biosystems) and human cyclophilin A 
(4326317e) Vic-labeled Pre-Developed Assay Reagent (Applied Biosystems); the 15-μl final 
reaction volume contained 1× TaqMan Universal PCR Master Mix (Applied Biosystems) and 
1× Assay-on-Demand. cDNA (25 ng/well) was amplified with the following cycling 
conditions: 10 minutes at 95°C, followed by 50 cycles at 95°C for 15 seconds and 60°C for 1 
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minute. Each qRT-PCR measurement was performed in 3 technical replicates that were 
averaged and normalized to cyclophilin A. A 2-tailed Mann-Whitney U test was used to 
assess whether FGFR3/cyclophilin A log ratios differed between groups. 
Measurement of FGFR3 protein level regulation by miR-99a, miR-21, and miR-125b. To 
determine whether overexpression of miR-99a mimic or anti-miR, miR-21 mimic, and miR-
125b mimic affected FGFR3 protein expression, each respective microRNA was transfected 
into SNB19 parental cells, and relative FGFR3 expression was measured 48 hours later via 
immunoblot analysis (Santa Cruz Biotechnology Inc.). Band intensity was quantified and 
normalized to β-tubulin expression using Image J software (NIH). The experiment was 
replicated three times. 
Generation of FGFR3 WT and fusion constructs containing the 3′-UTR of FGFR3. To 
generate WT FGFR3 and FGFR3-TACC3 fusion constructs containing the 3′-UTR 
of FGFR3, the 3′-UTR of FGFR3 was amplified by PCR from a FGFR3 3′-UTR plasmid 
(SC215711; Origene Technologies) to introduce the NheI cloning sites at both sides 
(underlined below), using the forward primer 5′-GCTAGCGGGCTCGCGGACGTGAAG-3′ 
and the reverse primer 5′-GCTAGCGGTTAGCAACCAGGTGTC-3′. The PCR product was 
cloned into pCR2.1 and verified by DNA sequencing. FGFR3 3′-UTR was then digested 
with NheI from pCR2.1–FGFR3 3′-UTR and subcloned into the XbaI sites downstream of 
pcDNA3.1+ WT FGFR3 and pcDNA3.1+FGFR3-TACC3vectors. All constructs were verified 
by DNA sequencing. To determine the ability of miR-99a to regulate expression 
of FGFR3 3′-UTR–containing constructs, miR-99a or scrambled control was transfected and 
assayed via immunoblot as described previously. 
In vitro functional studies. An MTT assay was performed to measure cell viability. Cells were 
seeded at 650 cells/well in a 96-well plate in quadruplicate and allowed to attach overnight. 
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Cell viability was measured by incubating cells with 0.5 mg/ml MTT reagent in PBS (Sigma-
Aldrich) for two hours. MTT reagent was then aspirated, and cells were subjected to lysis 
with 100% DMSO. Plates were read at 590 nm using the Tecan SpectraFluor Microplate 
Reader and Magellan 6 software (Tecan Group Ltd.) at 48, 72, or 96 hours after cell plating. 
Cell proliferation was measured via BrdU incorporation assay at 7, 11, and 13 hours in 
triplicate. Briefly, cells were synchronized at G1 by starvation for three days. Fresh medium 
was then added, and the cells were incubated for 12 hours, followed by pulse labeling with 
20 mm BrdU for one hour at the indicated time points. The cells were stained with FITC-
conjugated anti-BrdU antibody, incubated with 7-aminoactinomycin-D (7-AAD), and 
quantified via flow cytometry. To determine whether FGFR3-TACC3 promotes colony 
formation in soft agar, empty vector, FGFR3-TACC3, WT FGFR3, and WT TACC3 SNB19 
or U251 stable cells were cultured in DMEM/F12 medium with 10% FBS in the log phase. 
The soft agar was prepared by mixing 1.5% sterile low melting point agarose in PBS with 
fresh medium at a 1:2 dilution. Soft agar (1 ml of 0.5%) was added to each well of a 6-well 
plate and kept at room temperature for 15 minutes. Cells were then harvested and 
suspended in 0.375% soft agar at 1,000 cells/ml. This cell suspension (1 ml) was added on 
top of the prepared base agar layer. The plates were incubated for two weeks and fed two 
times per week. Colonies were counted under a microscope, and relative colony size was 
measured using AxioVision 3.1 software. Scratch migration, or wound healing, assays were 
performed using the 33mm culture-inserts purchased from Ibidi. Within each chamber, 70 ul 
of a 500,000 cells/ml suspension was added.  Cells were incubated at 4°C until they 
reached confluence, at which point the chambers were removed, leaving behind a 500 um-
wide border that was absent of cells, referred to as the “scratch”. Cells were imaged at 5X 
every several hours until the scratch closed.  
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Gene expression microarray analysis on fusion clones. FGFR3-TACC3 fusion– or 
WT FGFR3–transfected SNB19 mixtures or clones were hybridized onto dual-channel 
Agilent Whole Human Genome 4 × 44K v1 microarrays. RNA from parental SNB19 cells 
was hybridized onto the reference channel. Microarray slides were imaged, and background 
adjusted probe intensities were calculated using Agilent Feature Extraction Software version 
9.1.3.1. Probe sequences were aligned against RefSeq 38 transcript sequences, and the 
probes were arranged into probesets based on the genes they aligned against. Background-
adjusted probe intensities were quantile normalized and summarized using the robust 
multiarray analysis (RMA) algorithm (Irizarry et al, 2003). Differential gene expression was 
calculated by comparing against the reference channel. Pathway analysis was performed 
using Ingenuity Pathway Analysis (IPA; version 11904312). Microarray was performed by 
Limei Hu. Microarray files have been deposited in GEO (accession no. GSE42401). 
Intracranial xenograft implantation and tissue preparation. Male athymic mice (nu/nu) were 
implanted in the brain with EV, FGFR3-TACC3 fusion, or WT FGFR3 cells. Briefly, mice 
were anesthetized with 0.25 ml of a cocktail of 10 mg/ml ketamine and 1 mg/ml xylazine, 
and cells were implanted using cranial guide screws as previously described (Lal et al, 
2000). A Hamilton syringe and microinfusion syringe pump (0.5 ml/min; Harvard Apparatus) 
were used to implant 1 × 106 cells into the brain of ten mice simultaneously, as described 
previously (Nakamizo et al, 2005). Upon detection of an external tumor or obvious declining 
health, mice were sacrificed by intracardiac perfusion of PBS and 4% paraformaldehyde. 
Brains were extracted and fixed in 10% formalin for 24 hours, embedded in paraffin, and 
sectioned into 5-mm slices. 
Immunohistochemical staining. For immunohistochemical staining, Dako Envision+System–
horseradish peroxidase and diaminobenzidine (DAB) were used (Dako). Briefly, after 
antigen retrieval for 10 minutes in 0.1 M citrate buffer (pH 6.0) or 1 mM EDTA (pH 8.0) and 
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subsequent incubation in peroxidase block solution for 5 minutes at room temperature, the 
sections were incubated overnight at 4°C with rabbit anti-human FGFR3 (1:600; Abcam), 
pSTAT3 (1:200, Tyr705 D3A7; Cell Signaling Technology), and pERK (1:200, T202/Y204; 
Cell Signaling Technology). The sections were incubated in peroxidase-labeled polymer for 
30 minutes at room temperature, and the signals were revealed with DAB+ substrate–
chromogen solution. For negative controls, primary antibodies were replaced with PBS. 
Localization. Fusion localization was performed by using the Q Proteome Cell Compartment 
Kit (Qiagen) according to manufacturer’s instructions. Briefly, cells were lysed and 
differential centrifugation performed using various buffer systems to isolate the cytosol, 
membrane, nuclear, and cytoskeletal fractions. Cell fractions were then run on an 
immunoblot. Immunofluorescence was performed and imaged via confocal microscopy.  
bFGF and EGF stimulation. To determine whether the FGFR3-TACC3 fusion exhibits ligand 
dependence or independent firing, EV, FGFR3-TACC3 fusion, and WT FGFR3 cells were 
seeded in 6-well plates and incubated with 50 ng/ml bFGF or EGF ligand for 30 minutes at 
37°C. Cells were then harvested and subjected to immunoblot, probing for FGFR3, 
phosphorylated ERK, total ERK, and actin (Santa Cruz Biotechnology Inc.). 
Drug treatment studies. For studies measuring cell viability after U0126, WP1066, 
PD172074, or TMZ drug treatments, EV, WT FGFR3, and FGFR3-TACC3 fusion cells were 
plated at 100,000 cells/well in a 96-well plate. 12 hours after plating time, “0” was read to 
ensure cells were plated in equal numbers. At this time, drugs were added in increasing 
concentrations, with DMSO only as control. Plates were assayed 48 hours later, and values 
were normalized to DMSO controls. Cells were also seeded in 6-well plates and incubated 
with each inhibitor for one hour. These cells were assayed via immunoblot to determine the 
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potency of each drug concentration. A subG1 assay was performed on cell lysates by use of 
propidium bromide and analyzed via flow cytometry.  
Statistics. Unless otherwise indicated, data are represented as mean ± SEM. Statistical 
analyses were performed using Fisher exact test, Mann-Whitney U test, 2-way ANOVA, 1- 
or 2-tailed Student’s t test, and log-rank test, as indicated. Activation z scores were 
calculated as defined in the Ingenuity white paper “Ingenuity Downstream Effects Analysis in 
IPA.” Mice that died of causes other than cancer were considered censored. A P value of 
0.05 or less was considered significant. 
Study approval. Glioma tissue samples from the Brain Tumor Center tissue bank of the 
University of Texas MD Anderson Cancer Center were collected under an institutional 
review board–approved protocol. Glioma tissue samples from the Tumor Tissue Bank of the 
Tianjin Medical University Cancer Institute and Hospital were collected with approval from 
the institutional review board. All subjects provided informed consent of their participation in 
the study. Implantation of cells into the brains of male athymic mice were performed 
according to institution-approved protocols.  
Note: A portion of these materials and methods were obtained with permission from a 
published study in The Journal of Clinical Investigation (Parker et al, 2013a).  
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CHAPTER 3: Results 
 
3.1 The FGFR3-TACC3 fusion gene occurs in 8.3% of GBM patients 
Rationale. Recurrent fusion genes have been reported in a variety of cancers, beginning 
with the initial discovery of the BCR-ABL1 fusion in chronic myeloid leukemia (Rowley, 
1973b). The development of next-generation sequencing provided an enormous opportunity 
to discovery fusion genes that were unable to be detected using conventional 
methodologies. Furthermore, as of 2009 a recurrent fusion gene in glioma had yet to be 
reported. Therefore, by using next-generation deep sequencing technology, we 
hypothesized a recurrent fusion gene could be identified in glioma.  
Results. To determine whether recurrent fusion genes existed in glioma, whole 
transcriptome sequencing was performed on glioma tissues of varying grades. RNA from 
tissues were grouped together by grade, forming RNA pools. Adult normal brain was used 
as a control. RNA-seq reads that spanned exon-exon junctions connecting two discrete 
genes were prioritized according to specific criteria (Figure 5).  
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Figure 5. Fusion filtering algorithm. A fusion-filtering algorithm produced a ranked list of 
fusion candidates while filtering out false positives. Bioinformatics analysis was performed 
by Matti Annala. Used with permission from Parker, B.C., Annala, M.J., Cogdell, D.E., 
Granberg, K.J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The 
tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. The 
Journal of clinical investigation 123, 855-865. 
 
The fusion with the highest recurrence rate that satisfied all criterions contained the 
Fibroblast Growth Factor Receptor 3 (FGFR3) gene linked to the Transforming Coiled-Coil 
containing protein 3 (TACC3) gene. This fusion, FGFR3-TACC3, contained four unique 
reads, with 16 reads in total (Figure 6). Interestingly, this fusion was found in a GBM pool, 
and was not found in any low grade or normal brain pools. To determine whether fusion 
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positive patients existed in The Cancer Genome Atlas (TCGA) database, the same fusion-
filtering algorithm was applied and two more positive patients were identified.  
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Figure 6. Breakdown of fusion candidate discovery (A) yielded the top fusion candidate, 
FGFR3-TACC3, based upon 16 reads, four of which were unique (B). Adapted and used 
with permission from Parker, B.C., Annala, M.J., Cogdell, D.E., Granberg, K.J., Sun, Y., Ji, 
P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The tumorigenic FGFR3-TACC3 gene 
fusion escapes miR-99a regulation in glioblastoma. The Journal of clinical investigation 123, 
855-865. 
 
 The fusion was then validated using RT-PCR. Specifically, primers were designed 
that flanked the fusion breakpoint, one on the FGFR3 side and another on the TACC3 side 
of the breakpoint. PCR was then performed, and the resulting PCR product sequenced. If 
the sequenced result contained both FGFR3 and TACC3 genes, then the patient was 
considered positive for the FGFR3-TACC3 fusion. The fusion was found in 4/48 GBM 
patient samples (8.3%), but not in any lower grade or normal brain samples. Three separate 
fusion breakpoints were observed, which contained variable breakpoints in the TACC3 
gene. However, all fusion variants contained the same breakpoint on the FGFR3 side, exon 
18. One variant connected exon 19 of FGFR3, but because this exon does not have a 
splicing donor site, it instead fused exon 18 of FGFR3. The first and most common variant 
connected to TACC3 exon 11 (Figure 7 A,B), while a longer variant was found which 
connected to TACC3 exon 4.  
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Figure 7. FGFR3-TACC3 fusion validation. Exon transcript structures and 
electropherograms from FGFR3-TACC3 positive patient samples (A) along with protein 
domain map (B). RT-PCR was performed by David Cogdell. Adapted and used with 
permission from Parker, B.C., Annala, M.J., Cogdell, D.E., Granberg, K.J., Sun, Y., Ji, P., Li, 
X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The tumorigenic FGFR3-TACC3 gene fusion 
escapes miR-99a regulation in glioblastoma. The Journal of clinical investigation 123, 855-
865. 
 
 The nucleotide sequence of the fusion lead us to believe it translated into an in-frame 
fusion protein. To test this, SNB19 and U251 cell lines were transfected with the coding 
region of both fusion variants, the shorter variant with breakpoint at TACC3 exon 11, known 
as “Fusion S,” or longer variant with breakpoint at TACC3 exon 4, known as “Fusion L.”  
Whole cell lysates were then run on a gel and immunoblotted using an antibody that 
recognized the N-terminal of FGFR3. This particular epitope was chosen because the fusion 
lacked the C-terminal of FGFR3; therefore an antibody that recognized the C-terminal of 
FGFR3 would therefore not recognize the fusion (Figure 8A). The fusion was easily 
recognized by a shift upwards on the blot, indicative of the extra TACC3 domain. We then 
tested the ability of a C-terminal TACC3 antibody to recognize the fusion. Unfortunately, the 
fusion was unable to be recognized by this antibody, indicating the epitope of this particular 
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antibody must be upstream of TACC3 exon 4 (Figure 8B). To determine whether fusion 
positive patients could be visualized via immunoblot, we then ran RT-PCR fusion positive 
patient samples alongside cell line controls, containing either stable cell lines (indicated by 
asterisk) or transiently transfected cell lines. Fusion positive patients were easily observed 
via immunoblot, and showed strong band patterns (Figure 8C).  Interestingly, a single lower 
molecular weight band was observed in patient GBM-19, although this particular patient was 
fusion negative. Efforts to determine whether this patient contained an FGFR3 splice variant 
were inconclusive. Immunohistochemistry is a useful tool for diagnostic purposes in the 
clinic. Fusion positive patients showed strong FGFR3 staining, indicating the presence of 
the fusion in these samples. Interestingly, all fusion negative patient samples, as well as 
normal brain samples, showed very low to no levels of FGFR3 WT (Figure 8D).   
 
Figure 8. The FGFR3-TACC3 fusion forms an in frame fusion protein. Schematic of 
antibody binding to the N terminal of FGFR3 WT or FGFR3-TACC3 protein (A). Ability of N-
terminal domain to distinguish fusion from FGFR3 WT stable cell lines. A C-terminal TACC3 
antibody does not recognize the fusion (B). Fusion-positive patient samples at RNA level 
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show strong fusion protein expression in both immunoblot (C) and immunohistochemical 
analysis (C). Adapted and used with permission from Parker, B.C., Annala, M.J., Cogdell, 
D.E., Granberg, K.J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The 
tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. The 
Journal of clinical investigation 123, 855-865. 
 
3.2 The FGFR3-TACC3 fusion escapes microRNA regulation 
Rationale.  Both immunoblotting and immunohistochemical analyses revealed that fusion-
negative patient samples, as well as normal brain, showed little to no FGFR3 WT 
expression. However, fusion positive patients showed high fusion protein expression. Upon 
inspection of the fusion transcript sequence, we observed that the 3’ UTR of FGFR3 was 
lost upon formation of the fusion (Figure 9A). Therefore, we hypothesized that the fusion 
was expressed because it lacked the 3’ UTR of FGFR3, enabling it to be undetected by 
microRNA that normally keep FGFR3 WT levels in check. 
Results. To determine whether FGFR3 WT expression was decreased in GBM and brain 
tissues because of microRNA regulation, the highest expressed microRNA in GBM and 
normal brain were determined. Specifically, small RNA sequencing was performed on the 
same pools of glioma and normal brain tissues that were originally used to discover the 
fusion. A ranked list of microRNA was produced (Figure 9B).  The Targetscan.org software 
was then utilized to determine whether any of these highly expressed microRNA was 
predicted to target FGFR3 WT. Interestingly, miR-99a, one of the highest expressed 
microRNA in both GBM and normal brain, was predicted to target FGFR3 WT (Figure 9A).  
 To determine whether miR-99a indeed targeted FGFR3 WT in GBM, the 3’ UTR of 
FGFR3 was cloned in an expression vector alongside the luciferase gene. Site-directed 
mutagenesis was performed to delete the miR-99a binding site (Figure 9A). Then, the WT 
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FGFR3 3’ UTR (WT) or miR-99a binding site deleted UTR (Mut.) was transfected into 
SNB19 cells. These cells were then transfected with miR-99a, and luciferase assay 
conducted. Luciferase activity was significantly decreased upon transfection of WT UTR, 
while the Mut. UTR showed no change in luciferase activity (Figure 9C). These results 
indicate that indeed miR-99a targets the 3’ UTR of WT FGFR3 in GBM.  
 To determine whether these results translated to FGFR3 expression levels, control, 
miR-99a mimic, or miR-99a anti-miR was transfected into SNB19 cell lines (Figure 9D), 
which resulted in an inverse correlation between FGFR3 WT RNA expression and miR-99a 
(Figure 9E). This same pattern was also observed at the protein level (Figure 9F,G).  
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Figure 9. MiR-99a is overexpressed and targets FGFR3 in GBM. Schematic showing the 
location of the miR-99a binding site in the 3′-UTR of WT FGFR3 and its loss in the FGFR3-
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TACC3 fusion transcript and construct with the binding site deleted (mutant) (A). Pie chart 
illustrating high miR-99a expression in both GBM and normal brain. Expression values were 
calculated based on pooled small RNA sequencing (B). Luciferase assay of WT FGFR3 3′-
UTR versus mutant after miR-99a overexpression (C). qRT-PCR of miR-99a in parental 
SNB19 cells after transfection of control, miR-99a mimic, or anti–miR-99a (D). qRT-PCR (E), 
immunoblotting (F), and densitometry (G) of FGFR3 in parental SNB19 cells after 
transfection of control, miR-99a mimic, or anti-miR. Error bars denote SEM (K). **P < 0.01, 
***P < 0.001, Mann-Whitney U test. Used with permission from Parker, B.C., Annala, M.J., 
Cogdell, D.E., Granberg, K.J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. 
(2013a). The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in 
glioblastoma. The Journal of clinical investigation 123, 855-865. 
 
 To further validate that the fusion is able to be highly expressed because it lacks the 
3’ UTR of FGFR3, the 3’ UTR was cloned back onto the coding region of both FGFR3 WT 
and the fusion (Figure 10A,B). Cells were transfected in duplicate with EV, WT FGFR3 
lacking the 3’ UTR, or the WT FGFR3 coding region with 3’ UTR attached. Then, cells were 
transfected with either control miRNA, or miR-99a. Whole cell lysates were taken and 
samples immunoblotted with antibodies recognizing FGFR3 and β-tubulin as a loading 
control. FGFR3 protein expression decreased only when the 3’ UTR of FGFR3 was 
transfected along with miR-99a (Figure 10C). This experiment was repeated, but with the 
coding region of the fusion, or fusion with 3’ UTR of FGFR3 added. The same result was 
obtained (Figure 10D).  
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Figure 10. The FGFR3-TACC3 fusion escapes miR-99a regulation. Schematic of 
WT FGFR3 (A) and FGFR3-TACC3 fusion (B) cDNA, with or without FGFR3 3′-UTR 
attached. Immunoblot of EV, WTFGFR3, and WT FGFR3 plus FGFR3 3′-UTR after 
transfection with miR-99a (C). Immunoblot of EV, FGFR3-TACC3 fusion, or FGFR3-
TACC3 fusion plus FGFR3 3′-UTR after miR-99a transfection (D). Relative densitometry 
(below) was normalized to β-tubulin. Xia Li contributed to cloning experiments. Used with 
permission from Parker, B.C., Annala, M.J., Cogdell, D.E., Granberg, K.J., Sun, Y., Ji, P., Li, 
X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The tumorigenic FGFR3-TACC3 gene fusion 
escapes miR-99a regulation in glioblastoma. The Journal of clinical investigation 123, 855-
865. 
 
 TargetScan.org analysis revealed that out of the highest expressed microRNA, miR-
99a was the only predicted to target FGFR3 WT. To validate this result, SNB19 cells were 
transfected with control microRNA, miR-99a, miR-21, and miR-125b. As expected, only miR-
99a was able to deplete FGFR3 mRNA and protein expression (Fig. 11A-C).  
Bladder cancer is known to exhibit activating FGFR3 mutations and amplification. To 
determine whether there was an inverse correlation between FGFR3 expression and miR-
99a levels, GBM cell lines U373, U87, and SNB19 were run on an electrophoresis gel 
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alongside bladder cancer cell lines SW780, RT112, and RT4. All bladder cancer cell lines 
exhibited increased FGFR3 WT expression compared to all three GBM cell lines (Figure 
11D). To determine whether these tissues contained lower miR-99a, qRT-PCR was 
performed measuring relative levels of miR-99a in these samples. As expected, GBM cell 
lines exhibited higher miR-99a expression compared to all three bladder cancer lines 
(Figure 11E). To determine the ability of the fusion to target miR-99a, relative levels of miR-
99a were examined in fusion positive and negative patient samples, and no difference was 
observed (Figure 11F).  These results conclusively show that the fusion is able to bypass 
miR-99a regulation via loss of the 3’ UTR of FGFR3. These results also shed light on why 
levels of FGFR3 WT are so low in normal brain and GBM, as they’re under negative 
regulation of the highly expressed miR-99a in these tissues.  
 
Figure 11. Of the highest expressed miRNA in GBM, only miR-99a suppresses FGFR3 
expression. Upon miR-99a, -21, or -125b transfection, relative FGFR3 mRNA or protein 
levels were measured by qRT-PCR (A), immunoblotting (B), and densitometry (C), 
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respectively. Error bars, s.e.m. P- values calculated using Student’s t-test. *P<0.05; 
***P<0.001. FGFR3 immunoblot and miR-99a qRT-PCR for three GBM and three bladder 
cancer (BC) cell lines (D). FGFR3 protein level is inversely correlated with miR-99a (E). 
There is no difference in miR-99a expression in fusion positive or negative patient samples. 
Adapted from and used with permission from Parker, B.C., Annala, M.J., Cogdell, D.E., 
Granberg, K.J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The 
tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. The 
Journal of clinical investigation 123, 855-865. 
   
3.3 The FGFR3-TACC3 fusion activates ERK and STAT3 signaling 
Rationale. The FGFR3 is a RTK that activates the canonical Erk, Stat3, and Akt signaling 
pathways (Dailey et al, 2005). Because the fusion contained the majority of FGFR3, we 
hypothesized that the fusion would activate Erk, Akt, and Stat3 signaling. The ability of the 
fusion to activate these pathways was then determined. 
Results. To determine whether the fusion activated canonical FGFR3 WT signaling 
pathways, EV, Fusion, and FGFR3 WT cells were run on an immunoblot and immunoblotted 
for FGFR3, STAT3, ERK, and AKT. GAPDH was used as a loading control. The fusion was 
found to primarily activate ERK and STAT3 signaling, with little to no effect on AKT 
signaling, on either transiently transfected (Figure 12A) or stable cell lines (Figure 12B). For 
functional studies, stable clones were selected from fusion and FGFR3 WT mixture cells. 
Once again, fusion-expressing cells showed high ERK activation compared to EV control 
(Figure 12C).  
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Figure 12. The FGFR3-TACC3 fusion promotes ERK and STAT3 activity. Downstream 
analysis of transient (A) and stable (B) fusion cell lines indicates the major downstream 
molecules activated are STAT3 and ERK. AKT is not significantly activated by the presence 
of the fusion. SNB19 cell lines were transfected with either fusion or WT cDNA constructs 
and stable clones selected. Subsequent protein expression is can be visualized via 
immunoblot (C). Adapted from and used with permission from Parker, B.C., Annala, M.J., 
Cogdell, D.E., Granberg, K.J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. 
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(2013a). The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in 
glioblastoma. The Journal of clinical investigation 123, 855-865. 
 
3.4 The FGFR3-TACC3 fusion exhibits an oncogenic phenotype in vitro  
Rationale. The abilities of a cell to divide uncontrollably and invade nearby tissues are 
hallmarks of cancer, described in the groundbreaking review by Weinberg and Hanahan 
(Hanahan & Weinberg, 2011). Therefore, because the fusion was discovered in high-grade 
glioma tissue, we hypothesized that the fusion was oncogenic in vitro. The ability of the 
fusion to promote an oncogenic phenotype in vitro was also determined.  
Results. To determine whether the fusion exhibited an oncogenic phenotype in vitro, EV, 
FGFR3 WT, and fusion cell lines were subject to an MTT cell viability assay over the course 
of three days. Briefly, cells were seeded in replicates of 6 in a 96-well plate and assayed 
every 24 hours. Over the course of the experiment, there were more numerous fusion cells 
indicated by a higher absorbance measurement, concluding that fusion cells proliferate at a 
faster rate than either EV or FGFR3 WT cells (Figure 13A). To validate these results, a BrdU 
incorporation assay was performed and once again, fusion cells proliferated at a faster rate 
(Figure 13B).  
 Usually, non-cancerous cells will only divide when attached to a hard surface. 
Therefore, a measure of oncogenic activity in vitro is to perform a soft-agar colony formation 
assay, where cells are seeded in soft agar and measured for colony number and size over a 
period of time. The larger and more numerous colonies that form in soft agar is indicative of 
an oncogenic phenotype. Briefly, EV, TACC3 WT, FGFR3 WT, and fusion cells were seeded 
in triplicate in a 6 well plate, on top of soft agar and incubated at for several days. As 
expected, fusion cells showed larger and more numerous colonies, indicating they are 
oncogenic in vitro (Figure 13C).  
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 To gain greater insight into the gene sets activated by the fusion, a microarray 
experiment was performed on extracted RNA from EV and fusion expressing SNB19 cells 
followed by Ingenuity Pathway Analysis (IPA). Interestingly, fusion cells exhibited expression 
of genes that correlate with tumorigenesis, cancer, and neoplasia – further confirming that 
the fusion activates specific gene pathways promoting an oncogenic phenotype.  
 To determine whether fusion cells migrated at a faster rate, EV, FGFR3 mixture, 
Fusion mixture, and Fusion clone 5 (Figure 12C) cells were subject to a scratch migration 
assay. Briefly, cells were seeded and allowed to grow to confluency. A scratch was then 
made, and photographed over the course of 24 hours. Both Fusion mixture and Fusion 
clone 5 cells migrated at a faster rate compared to either EV or FGFR3 WT cells (Figure 
13F). Interestingly, fusion clone 5 cells also showed the highest degree of GTP-Rac 
activation (Figure 13E).  Therefore, these results collectively indicate the fusion is highly 
oncogenic in vitro, by exhibiting increased cell proliferation, anchorage-independent cell 
growth, expression of gene sets correlated with neoplasia and cancer, and cell migration.  
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Figure 13. The FGFR3-TACC3 fusion is oncogenic in vitro. The fusion promoted cell 
proliferation in both MTT (B), and BrdU incorporation assays (B), as well as anchorage-
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independent cell growth (C). The fusion exhibited expression of gene sets correlated with 
tumorigenesis (D), and promoted cell migration (E,F). ***P<0.001. Adapted from and used 
with permission (A-D) from Parker, B.C., Annala, M.J., Cogdell, D.E., Granberg, K.J., Sun, 
Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The tumorigenic FGFR3-TACC3 
gene fusion escapes miR-99a regulation in glioblastoma. The Journal of clinical 
investigation 123, 855-865.Dr. Ping Ji assisted with BrdU incorporation assay. 
 
3.5 The FGFR3-TACC3 fusion is oncogenic in vivo  
Rationale. Mouse models are valuable tools to measure the causal effect of potential 
oncogenes before targeted therapy can be introduced in clinical trials. Mouse models can 
also be used to test the efficacy and toxicity of potential drug therapeutics.  
The fusion exhibited an oncogenic phenotype in vitro, including cell proliferation, 
anchorage-independent cell growth, and migration. Further, upon analysis of genes 
expressed by the fusion indicated gene sets whose expression correlated with oncogenic 
gene networks. Because of this, we hypothesized that the fusion was oncogenic in vivo. 
Therefore, the oncogenic potential of the fusion in vivo was examined.  
Results. To determine whether the fusion was oncogenic in vivo, an orthotopic intracranial 
xenograft mouse model was utilized. Briefly, EV, Fusion mixture (FTmix), fusion Clone 5 
(FThigh), FGFR3 WT mixture, or FGFR3 Clone 2 (FGFR3 high) were implanted into the 
brains of immune incompetent mice (Figure 14A). Mice are then sacrificed upon physical 
inspection of tumor or hydrocephalus. Fusion-implanted mice died at a significantly faster 
rate compared to either EV or FGFR3 WT mice (Figure 14B, C). Interestingly, FGFR3 WT-
implanted mice died at a similar rate to EV (Figure 14B, D). These results suggest that the 
fusion, indeed, in oncogenic in vivo, and that the loss of the C-terminal FGFR3, or the 
presence of both FGFR3 and TACC3 are required to confer this oncogenic phenotype.  
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 To observe if the same signaling pathways activated by the fusion in vitro were also 
activated in vivo, brains of tumor burdened mice were sectioned and stained for FGFR3, 
phosphor-STAT3, and phosphor-ERK. Agreeing with in vitro results, mice that had fusion-
positive tumors had increased activation of both signaling pathways (Figure 14E).   
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Figure 14. The FGFR3-TACC3 fusion is tumorigenic in vivo. SNB19 stabling expressing cell 
lines were transplanted into the brains of immunocompromised mice (A). Survival curves of 
cell lines were analyzed (B-D). Immunohistochemistry confirmed the fusion activates ERK 
and STAT3 signaling (E). Adapted and used with permission from Parker, B.C., Annala, 
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M.J., Cogdell, D.E., Granberg, K.J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. 
(2013a). The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in 
glioblastoma. The Journal of clinical investigation 123, 855-865. Joy Gumin, M.S. from Dr. 
Frederick Lang’s and Dr. Yan Sun contributed to these experiments.  
 
3.6 The FGFR3-TACC3 fusion localizes to the nucleus 
Rationale. WT FGFR3 protein has been described to localize to the cell membrane, while 
WT TACC3 is found in the cytoplasm and nucleus (Garriga-Canut & Orkin, 2004). FGFR3 
has been found to localize to the nucleus in some cancers, whereas activating FGFR3 
mutations in skeletal disorders show limited cell-surface FGFR3 (Bonaventure et al, 2007; 
Zammit et al, 2001). We hypothesized that the fusion would localize to the membrane and 
nucleus, as it contained portions of both FGFR3 and TACC3.  
Results. To determine where in the cell the fusion localized, a cell fractionation experiment 
was performed on EV, fusion, FGFR3 WT, truncated FGFR3, and TACC3 overexpressing 
cell lines. The truncated FGFR3 construct contains the portion of WT FGFR3 contained 
within the fusion (Figure 15A). Briefly, cellular compartments were separated via differential 
centrifugation and various buffer systems, as described in the Q Proteome Cell 
Fractionation kit (see Materials and Methods). The various cell fractions were then run on a 
polyacrylamide gel and subject to immunoblotting. Using the FGFR3 antibody the location of 
FGFR3 containing proteins was determined. The fusion was found to primarily localize to the 
membrane, nuclear, and cytoskeletal fraction, while WT FGFR3 and tFGFR3 were 
predominantly located in the membrane fraction. WT TACC3 protein was predominantly 
found in the cytoplasm fraction. GAPDH was used as a cytoskeletal control, lamin as 
nuclear control, and vimentin as cytoskeletal control. EVcyto was run on the nuclear and 
cytoskeletal fraction blots as a transfer control (Figure 15B).  
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 To further validate these results, immunofluorescence was performed on FGFR3 WT 
and fusion-overexpressing SNB19 cells. Once again we can see that the fusion primarily 
localizes to the membrane and nuclear regions, while WT FGFR3 is on the membrane 
(Figure 15C).  
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Figure 15. The fusion is localized to the membrane, nucleus, and cytoskeleton. A 
schematic of either wt FGFR3 or TACC3 constructs, or test constructs are shown (A) that 
are used in cell fractionation experiments (B) as well as immunofluorescence (C).  
 
 
3.7 The FGFR3-TACC3 fusion is activated by bFGF ligand 
Rationale. Several (>20) FGFR activating ligands have been described, which differentially 
activate the four FGFR isoforms. Basic FGF “bFGF” has been shown to activate most 
receptor isoforms (Dvorak & Hampl, 2005), so we sought to determine whether bFGF could 
therefore also activate the fusion. Because EGFR amplification is common in GBM, we also 
sought to determine whether the fusion would respond to EGF treatment, or whether it 
exhibited constitutive activation. ERK activity was used as a measure of receptor activation 
following treatment with either bFGF or EGF on serum starved cells.  
Results. To determine if the fusion responds to bFGF treatment, EV, FGFR3, and fusion 
expressing cells were serum starved and then treated with 50ng/mL bFGF for 5, 30, and 60 
minutes. ERK activity was measured as a readout for receptor activity. Interestingly, fusion 
cells exhibited ERK activity in the absence of serum, indicating the fusion is constitutively 
activated. However, ERK activity increased upon treatment with bFGF, indicating that the 
fusion, indeed, responds to ligand treatment (Figure 16A).  
EGFR is a commonly amplified RTK in GBM. EGFR is activated by EGF ligand 
binding, resulting in Grb2 recruitment and subsequent ERK activation. To determine 
whether EGF activated the fusion, EV, FGFR3 WT, and fusion cells were serum starved and 
then incubated with 50ng/mL EGF for varying amounts of time. Fusion cells did not exhibit 
differential ERK activation in the presence of EGF, indicating that they do not respond to 
EGF ligand. Also, because EGFR expression is the same in these cell lines (Figure 16B), 
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these results suggest that the fusion recruits ERK away from EGFR signaling pathways, and 
become “addicted” to fusion-induced ERK signaling.  
 
Figure 16. The FGFR3-TACC3 fusion is activated by bFGF ligand treatment (A), but not 
EGF treatment (B). Panel (A) is used with permission from Parker, B.C., Annala, M.J., 
Cogdell, D.E., Granberg, K.J., Sun, Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. 
(2013a). The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in 
glioblastoma. The Journal of clinical investigation 123, 855-865. 
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3.9 The FGFR3-TACC3 fusion is chemoresistant  
Rationale. TMZ is the frontline chemotherapy agent for the treatment of GBM, and was 
approved by the United States Food and Drug Administration in 2005. Chemotherapy 
treatment has been found to prolong survival in 25% of patients with GBM (Fine et al, 1993). 
One of the biggest hurdles with TMZ treatment is that tumors can become resistant t, and 
can recur with a vengeance. Therefore, we sought to determine whether the fusion 
promoted chemoresistance, and if this was due to expression of genes associated with cell 
survival and DNA repair.  
Results. To determine whether fusion positive cells were targetable by TMZ, a sub G1 assay 
was performed on EV, fusion, or FGFR3 WT cells upon treatment with 50μM TMZ. Fusion 
expressing cells exhibited less sub g1 activity or apoptotic activity, suggesting a 
chemoresistant phenotype (Figure 18A). To validate this finding, EV, fusion, FGFR3 WT, 
and tFGFR3 expressing cells were treated with increasing doses of TMZ over the course of 
7 days. Fusion expressing cells exhibited greater cell survival compared to all other cell 
types (Figure 18B).  
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Figure 18. The FGFR3-TACC3 fusion is chemoresistant. Result determined by sub G1 
apoptosis assay (A) and MTT cell viability assay (B). 
 
3.1.1 The FGFR3-TACC3 fusion is sensitive to targeted therapy 
Rationale. The fusion was found to primarily activate ERK and STAT3 signaling, but was 
found to be chemoresistant. Therefore, we hypothesized that fusion was more sensitive to 
ERK, STAT3, and FGFR3 inhibitors. If these inhibitors were found to be potent on fusion 
cells, then it would provide insight into whether these drugs may be useful for fusion-positive 
patients future clinical trials.  
Results. To determine whether the fusion was sensitive to ERK inhibition, EV, FGFR3 WT, 
and fusion cells were treated with increasing doses of the MEK inhibitor U0126. MEK is 
directly upstream of ERK, and directly activates it via phosphorylation. Therefore, U0126 is 
thought to directly impact ERK activity. Briefly, cells were seeded in a 96 well plate and 
incubated with varying doses of U0126 (with DMSO only as control) for 48 hours. Cells were 
then assayed via MTT and normalized to DMSO controls. Fusion positive cells were more 
sensitive to MEK inhibitor U0126 at all doses (Figure 20A). As a control for U0126 potency, 
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a six-well plate was also utilized and whole cell lysates obtained after treatment with varying 
doses of inhibitor. Lysates were run on a polyacrylamide gel and immunoblotted with 
FGFR3, phosphor-ERK, total ERK, and β-tubulin as loading control. A ponceau stain was 
also performed to ensure correct loading. As expected, fusion cells showed increased ERK 
activity upon treatment with DMSO control. The potency of U0126 is observed by a steady 
decrease in ERK activity with increasing drug concentration (Figure 20B).  
 STAT3 activity was also increased in fusion expressing cells. To determine whether 
fusion cells were more sensitive to STAT3 inhibitor WP1066, cells were treated with 
increasing doses over the course of 48 hours. Fusion expressing cells were found to be 
more sensitive to STAT3 inhibition (Figure 20C). The WP1066 doses chosen were effective 
at inhibiting STAT3 activity (Figure 20D).  
 Because levels of FGFR3 WT are low in normal brain and GBM, treatment with an 
FGFR3 specific inhibitor seems like a successful therapeutic option for fusion positive 
patients. Therefore, we sought to determine whether fusion positive cells were more 
sensitive to FGFR3 inhibition. As expected, fusion positive cells were indeed more sensitive 
to FGFR3 inhibition (Figure 20E,F).  
 These results suggest that fusion positive patients may benefit from treatment with 
ERK, STAT3, and FGFR3 inhibition, either alone or in combination. Whether these drugs 
are potent in vivo alone or in combination remains to be elucidated.  
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Figure 20. The FGFR3-TACC3 fusion is more sensitive to targeted therapy. MTT cell 
viability assays were performed using MEK (A), STAT3 (C), and FGFR (E) inhibitors. 
Immunoblotting confirmed the potency of each drug used (B,D,F). ***P<0.001. Adapted and 
used with permission from Parker, B.C., Annala, M.J., Cogdell, D.E., Granberg, K.J., Sun, 
Y., Ji, P., Li, X., Gumin, J., Zheng, H., Hu, L., et al. (2013a). The tumorigenic FGFR3-TACC3 
gene fusion escapes miR-99a regulation in glioblastoma. The Journal of clinical 
investigation 123, 855-865. 
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CHAPTER 4. Summary 
Fusion genes are extremely valuable discoveries in cancer, as they can serve both as 
prognostic markers and also as drug targets in a clinical setting. The first discovered and 
characterized fusions were found in leukemia, which proved to be successful therapeutic 
targets. With the advent of more powerful sequencing technologies, more fusion genes were 
unveiled in solid tumors. Using next-generation deep sequencing techniques, we discovered 
the recurrent fusion, FGFR3-TACC3 in GBM. We found the fusion to be extremely 
oncogenic both in vitro and in vivo. The fusion was found to escape microRNA regulation by 
loss of the 3’ UTR on FGFR3 upon formation of the fusion. Although resistant to treatment 
with TMZ, the fusion was sensitive to targeted therapy using FGFR, STAT3, and ERK 
inhibitors.  
 
Figure 22. Summary.   
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CHAPTER 5: Discussion 
 
5.1 The FGFR3-TACC3 fusion gene knows no cancer boundaries.  
Upon the initial discovery of the FGFR3-TACC3 fusion in GBM, the fusion was discovered in 
other cancers, including bladder, oral, and lung cancers (Williams et al, 2013a; Wu et al, 
2013b). Also, the fusion has recently been found in low-grade glioma by the TCGA working 
group. It’s extremely interesting how one particular fusion can form in very different cancer 
types. The specific FGFR3 isoforms are also reflected in these fusions, as FGFR3 IIIb 
isoform is typically expressed in epithelial tissues (i.e. bladder), while the IIIc isoform is 
expressed in mesenchymal tissues (i.e. brain, lung) (Holzmann et al, 2012).   
Interestingly, other FGFR family fusions were also reported in a diverse array of solid 
cancers (Figure 22). Two of three FGFR1 fusions contained FGFR1 as the 3’ partner gene, 
while all FGFR3 and most of FGFR2 fusions contained FGFR as the 5’ partner gene. 
Interestingly, All FGFR2 and FGFR3 fusions (with one isolated FGFR2 case, SLC45A3-
FGFR2) contained the same exonic breakpoint – exon 18 or exon 19 in either FGFR2 or 
FGFR3, respectively. Interestingly, the SLC45A3-FGFR2 fusion was found in prostate 
cancer, and exhibits similar expression mechanisms as the other commonly known prostate 
cancer fusion, TMPRSS2-ERG/ETV1/ETV4. Specifically, FGFR2 is fused to the promoter 
region of the androgen-driven gene SLC45A3 (Wu et al, 2013a). FGFR2 fusions contain the 
most diverse partner genes, while FGFR3 fusions fuse to only TACC3 and BAIAP2L1 genes 
[reviewed in (Parker et al, 2014)].  Because of the highly diverse array of FGFR family 
fusions, future efforts should focus on developing FGFR inhibitors that could potentially 
target several cancer types.  
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Figure 23. FGFR family fusions occur in a vast array of solid tumors. Included with 
permission from Parker, B.C., Engels, M., Annala, M., and Zhang, W. (2014). Emergence of 
FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. The 
Journal of pathology 232, 4-15. 
 
5.2 The FGFR3-TACC3 fusion is an oncogenic, driver event in GBM. 
Both in vitro and in vivo studies performed by us and others have shown that the FGFR3-
TACC3 fusion is oncogenic (Parker et al, 2013a; Singh et al, 2012). Specifically, the fusion 
promotes cell proliferation, migration, anchorage-independent cell growth, and is resistant to 
the frontline chemotherapy agent, TMZ. Fusion-implanted mice exhibited decreased survival 
in vivo, and exhibited high activation of STAT3 and ERK signaling pathways (Parker et al, 
2013a). The fusion contains the majority of FGFR3, which sheds light on why the fusion 
would activate canonical FGFR3 signaling pathways, including ERK and STAT3. However, 
using primary cell lines, another group found the fusion to inhibit ERK signaling (Singh et al, 
2012). TACC3 has also been linked to ERK signaling (Ha et al, 2013b), although it is 
unlikely that the small portion of TACC3 present within the fusion (coiled-coil domain only) 
alone promotes this phenotype. The ability of the fusion to promote ERK activity is not 
limited to GBM alone, but was also found in bladder cancer cell lines as well (Williams et al, 
2013a).  
Evidence suggests that the presence of the coiled-coil domain promotes ligand-
independent activation, as it allows the fusion to dimerize (Wu et al, 2013a). Supporting this 
hypothesis, we observed ERK activity in serum starved conditions, however we also 
observed an increase in ERK activity following ligand stimulation, indicating the fusion also 
responds to ligand treatment (Figure 16A,B). This phenomenon may provide evidence that 
the fusion can maintain signaling in unfavorable, nutrient-deprived environments that 
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normally would hinder growth, but can exert an even more aggressive phenotype when 
nutrients become available. 
 Genetic instability and heterogeneity are common traits observed in GBM patient 
samples. Specifically, patients typically exhibit oncogenic gene signatures that co-occur. We 
sought to determine whether the fusion was mutually exclusive, or existed concurrently with 
these commonly observed gene signatures. If we found that the fusion typically occurred 
alongside other genetic events, it could be inferred that the fusion was merely a passenger 
event to genetic instability. For example, if formation of an oncogene occurred in a region of 
a chromosome that formed a “hot spot”, and if the genes comprising the fusion were in the 
same genomic neighborhood, this could suggest a proximal neighbor effect. Interestingly, 
copy number analysis showed that the fusion was mutually exclusive with commonly 
amplified genes in GBM, including EGFR, MET, and PDGFRA (Parker et al, 2013a). 
Furthermore, because the fusion exists in several cancer types (and different cells of origin) 
further suggests the fusion is not a random passenger event of genetic instability. Therefore, 
these results suggest that the fusion is not a passenger event, but occurs in isolation to 
these other known oncogenes, suggesting the fusion itself is a driver event in GBM.  
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Figure 24. Reported oncogenic phenotypes of FGFR family fusions. Figure used and 
adapted with permission from Parker, B.C., Engels, M., Annala, M., and Zhang, W. (2014). 
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid 
tumours. The Journal of pathology 232, 4-15. 
 
5.3 The FGFR3-TACC3 fusion escapes microRNA regulation. 
Immunohistochemical and immunoblotting results showed that levels of WT FGFR3 were 
very low in normal brain and GBM (Figure 8). However, because the fusion contained the 
majority of FGFR3, and fusion-positive patients exhibited high protein expression, it caused 
us to question the mechanism as to how the fusion could bypass the negative regulation 
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that characteristically kept FGFR3 WT levels low (Figure 25). Upon examination of the 
fusion transcript structure, we noticed that the 3’ UTR of FGFR3 was lost upon formation of 
the fusion. This led us to hypothesize that the fusion was able to bypass the regulation of a 
particular microRNA that would normally target WT FGFR3. We then performed small RNA 
sequencing on the same pool of patient samples used to originally discover the fusion, and 
indeed found a highly expressed miRNA in both GBM and normal brain that was predicted 
to target FGFR3 WT – miR-99a. We then validated that miR-99a targeted FGFR3 in GBM, 
and that levels of miR-99a negatively correlated with FGFR3 expression in both GBM and 
bladder cancer (Figure 9,10).  To further show that the fusion is able to bypass miR-99a 
regulation, we cloned the 3’ UTR of FGFR3 onto the coding region of the fusion, and then 
transfected with either control miRNA or miR-99a. These results confirmed that the fusion 
was highly expressed because it lacked this microRNA-regulated sequence. The ability of 
fusion genes to escape microRNA regulation has been described previously in adenoid 
cystic carcinoma. Specifically, the MYB-NFIB fusion is highly expressed because it lost the 
3’ UTR of MYB upon formation of the fusion. Therefore, although WT MYB is normally not 
expressed in these tissues, because this fusion bypasses microRNA regulation, it is 
overexpressed (Persson et al, 2009).  
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Figure 25. The FGFR3-TACC3 fusion escapes miR-99a regulation in GBM. Figure used 
and adapted with permission from Parker, B.C., Engels, M., Annala, M., and Zhang, W. 
(2014). Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum 
of solid tumours. The Journal of pathology 232, 4-15. 
 
5.5 Therapeutic implications of targeting the FGFR3-TACC3 fusion protein.  
TMZ is the frontline chemotherapy drug for the treatment of GBM. Therefore, we sought to 
determine whether fusion expressing cell lines were more sensitive or resistant to TMZ. By 
performing MTT cell viability and sub G1 apoptosis assays, we determined that the fusion 
promoted chemoresistance. To gain insight into how the fusion promoted chemoresistance, 
we looked at differential gene expression in fusion patient samples and cell lines compared 
to fusion negative samples and cell lines. Because MGMT is normally associated with 
chemoresistance, we hypothesized that the fusion promoted MGMT expression. However, 
we found that fusion-positive patients and fusion expressing cell lines did not show a 
statistically significant increase in MGMT expression.  
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 The fusion was found to promote ERK and STAT3 signaling. Therefore, we sought to 
determine whether fusion-expressing cell lines would be more sensitive to treatment with 
FGFR inhibitor PD173074, MEK (ERK) inhibitor U0126, or STAT3 inhibitor WP1066. By 
performing MTT cell viability assays, we found that fusion cell lines were more sensitive to 
treatment with these inhibitors. This data suggests that fusion positive patients may benefit 
from treatment with targeted therapy, but not conventional chemotherapy treatment. Future 
work will involve determining if these inhibitors or inhibitor combinations are successful in 
treating fusion-expressing cell lines when they are implanted into the brains of 
immunocompromised mice.  
 Because levels of WT FGFR3 are exceedingly low in the brain, treatment with an 
FGFR3 specific inhibitor for fusion positive patients appears to be an extremely attractive 
therapeutic option. Because levels of WT FGFR3 are low, this would limit off-target effects 
as the drug would presumably only target fusion-expressing cancer cells. However, there 
are no FGFR3-specific inhibitors that are able to cross the blood brain barrier at the present 
time. Efforts should focus on the development of an FGFR3 specific inhibitor that has the 
ability to cross the blood brain barrier, to allow for effective drug delivery.  
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CHAPTER 6: Future directions 
 
6.1 Elucidating the oncogenic result of losing the C-terminal of FGFR3  
In both in vitro colony formation assays and xenograft glioma models reported by us and 
others (Parker et al, 2013b; Singh et al, 2012), FGFR3 and TACC3 alone did not show 
transforming abilities suggesting the fusion of these two proteins confers a gain of 
oncogenic activity, a paradigm that is commonly accepted. One explanation is that the 
coiled-coil TACC domain can direct the kinase domain of the FGFR3 portion to some 
specific compartments of the cell and fire kinase activities in an inappropriate manner. This 
is supported by our cell fractionation experiments where we showed that the FGFR3-TACC3 
protein is abundant in the nucleus in contrast to FGFR3 itself.  
Alternatively, deletion of the C-terminal region of FGFR3 may also be functionally 
important. Recent publications have identified a negative regulatory domain, YLDL, in the C-
terminal domain of FGFR family members, which may play a role in receptor trafficking (Cha 
et al, 2009). In addition, it has been shown that a proline-rich sequence exists in the C-
terminal of all FGFR family members that serves as a recruitment site for GRB2 that 
terminates signaling of the receptor in serum starved conditions (Lin et al, 2012).  
We will also examine the oncogenic impact of key phosphorylation sites on FGFR3 
that are involved in promoting oncogenesis. We will determine the importance of the FGFR3 
C-terminal and TACC domains, as well as phosphorylation sites on the oncogenic activity of 
the fusion protein by deletion and or mutation of selected regions. 
 
6.2 Determine key phosphorylation sites on FGFR3-TACC3 
Strong evidence has accumulated over the last two decades suggesting that genomic 
instability is a hallmark of GBM. GBM is characterized by extensive copy number alterations 
and point mutations of critical genes. The fact that TACC3 has been shown to be important 
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for mitosis and can localize to the centrosome suggests that the FGFR3-TACC3 may cause 
aneuploidy. This hypothesis is supported by the observation that the fusion is localized to 
spindle poles and delayed mitotic progression leading to defects in chromosomal 
segregation (Singh et al, 2012). Evidence suggested that fusion-induced aneuploidy was 
“corrected” upon treatment with pan FGFR inhibitor PD173074 (Singh et al, 2012). The 
mechanisms through which the fusion protein affected mitosis and chromosomal 
segregation and the key regulatory switches on FGFR3 are not known.  Six phosphorylation 
sites are conserved across all FGFR family members, four of which are present within the 
fusion. Both Y647 and Y648 comprise the “activation loop”, whose phosphorylation is 
required for the conformational changes that accompany receptor activation. Wild-type 
TACC3 is known as a mitotic regulator that requires the interaction of several binding 
proteins during mitosis. One such protein is Aurora Kinase A, whose phosphorylation of 
TACC3 is required for proper localization of TACC3 to centrosomes and mitotic spindles 
during cell division, and for the recruitment of colonic, hepatic tumor overexpressed gene 
(ch-TOG) and clathrin to the mitotic spindle (Booth et al, 2011). In fact, evidence suggests 
that clathrin depletion shows the same phenotypic pattern as TACC3 depletion (Gergely et 
al, 2003; Royle et al, 2005), and ch-TOG requires Aurora Kinase A mediated activated 
TACC3 for localization to microtubules (Gergely et al, 2003).  Furthermore, deregulation of 
Aurora A Kinase has been implicated in several cancers and contributes to mitotic 
abnormality and chromosome instability (Fu et al, 2007) and is overexpressed in GBM and 
expression is correlated with poor patient prognosis (Figure 2). In this specific aim, we will 
first test the hypothesis that the TACC domain is responsible for the transportation of the 
attached FGFR3 kinase domain to the centrosome where it then forms a complex with ch-
TOG and Aurora A. In fact, inhibition of Aurora A with the selective small molecule inhibitor 
MLN8054 resulted in mislocalization of TACC3 and clathrin away from mitotic spindles and 
microtubules, suggesting that Aurora A Kinase is required for the initial recruitment of 
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TACC3. Aurora Kinase B, another Aurora kinase family member, has also been implicated 
in GBM, although to a lesser extent to Aurora Kinase A, and is thought to contribute to the 
aggressive behavior observed with GBM (Zeng et al, 2007). 
 Our cell fractionation experiments showed abundant localization of fusion protein in 
the nucleus. Therefore, it is very likely the fusion protein is not restricted to the centrosome. 
We propose to investigate whether the fusion protein interacts and regulates other 
chromosomal segregation machinery proteins that need kinase activation. The candidates 
for the proteins to study include Aurora A, Aurora B, Cyclin B1, ch-TOG and clathrin. We will 
carry out protein pull-down experiments to identify the binding proteins. 
 
6.3 Elucidating therapeutic options for FGFR3-TACC3 patients in vivo 
GBM is one of the most chemoresistant cancers. A major goal in GBM genomic studies is to 
identify specific genetic alterations that can be targeted for therapeutics for personalized 
medicine. Our work and that of our colleagues showed that FGFR3-TACC fusion is a 
recurrent genetic event occurring in up to 8% of GBM patients, and the protein product of 
this fusion gene is highly expressed in GBM cells due to escape of miR-99a regulation. MiR-
99a emerges as a major tumor suppressor miR with an increasing literature report in various 
cancers. The marked elevation of the fusion protein not only makes it an ideal marker for 
detection by a simple immunohistochemistry staining in a pathological laboratory, but also 
makes it a highly specific target for pharmacological inhibition. Several pharmaceutical 
companies are developing small molecule inhibitors for pan-FGFR that can cross the BBB, 
and there are efforts in developing FGFR3-specific inhibitors. In order to translate this 
important bench discovery into providing improved patient care, we will test compounds in 
multiple cell lines using in our xenograft mouse models and most importantly will test them in 
the spontaneous RCAS glioma model. Currently, the most powerful mouse model for 
spontaneous glioma development after molecular perturbation is the glial specific RCAS-tva 
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model, originally developed by Holland in the Varmus laboratory nearly 15 years ago 
(Holland & Varmus, 1998). Our group has used this model for the past ten years to illustrate 
that IGFBP2 as a key oncogene in glioma. We will use the RCAS model to complement the 
xenograft model to test whether expression of the FGFR3-TACC3 fusion may promote 
gliomagenesis, and possible therapeutics that could be implemented as a therapy for fusion-
positive patients. During the course of project, newer drugs that target FGFR3 may emerge 
and we will have a system in place to test these drugs when they become available. With 
our system in place, we can also test other drugs such as STAT3 and ERK inhibitors in 
combination with FGFR inhibitors based on our signaling studies.  
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